Strong on results.

before Otoscopic view of tympanic membrane in a patient who did not respond to ampicillin

after Same patient after ten days of Bactrim (trimethoprim and sulfamethoxazole/Roche) therapy

Copyright © 1985 by Hoffmann-La Roche Inc. All rights reserved.

Simple to take.

in acute otitis media

- **Penetrates and clears middle-ear fluid of susceptible strains of *H. influenzae* and *S. pneumoniae*[1]**
- **Reduces evidence of inflammation and bulging eardrum[2]**
- **Results in a reduction of fever, pain and other symptoms[2,3]**

Active against 86% of *H. influenzae in vitro*—even amoxicillin- and ampicillin-resistant strains

Overall, 86% of *Haemophilus influenzae* strains taken from sputum cultures prove susceptible *in vitro* to Bactrim.[4] In one study, 100% of 191 ampicillin-resistant *H. influenzae* isolates were susceptible to Bactrim.[5] However, *in vitro* data do not necessarily correlate with clinical results.

Active against 91% of *S. pneumoniae in vitro*

In sputum cultures of *Streptococcus pneumoniae,* the most frequent pathogen in acute otitis media, 91% of isolates show susceptibility *in vitro* to Bactrim.[4]

Excellent clinical activity—and economical

In comparative clinical trials in children with acute otitis media, Bactrim *b.i.d.* was unsurpassed by ampicillin, amoxicillin or cefaclor.[6]
And the average cost of Bactrim is lower than that of cefaclor and comparable to that of ampicillin and amoxicillin.[7]
Bactrim is indicated in acute otitis media due to susceptible organisms when it offers an advantage over other antimicrobials. Bactrim is contraindicated in pregnancy, lactation, infants under two months of age and documented megaloblastic anemia due to folate deficiency. To date, there are limited data on the safety of repeated use of Bactrim in children under two years of age.

Cherry-flavored suspension

Bactrim™ Pediatric

(trimethoprim and sulfamethoxazole/Roche)

B.I.D. for enhanced compliance.

References: 1. Klimek JJ *et al: J Pediatr 96:*1087-1089. Jun 1980. 2. Schwartz RH *et al: Rev Infect Dis 4:*514-516. Mar-Apr 1982. 3. Cooper J, Inman JS, Dawson AF: *Practitioner 217:*804-809, Nov 1976. 4. Antibiotic Sensitivity Report, Winter 1983. BAC-DATA Medical Information Systems, Inc. 5. Data on file, Hoffmann-La Roche Inc., Nutley, NJ. 6. Wormser GP, Keusch GT, Heel RC: *Drugs 24:*459-518, Dec 1982. 7. *Med Lett Drugs Ther 23:*93-95, Oct 30, 1981.

Please see summary of product information on the following page.

References: 1. Klimek JJ *et al: J Pediatr 96*:1087-1089, Jun 1980. 2. Schwartz RH *et al: Rev Infect Dis 4*:514-516, Mar-Apr 1982. 3. Cooper J, Inman JS, Dawson AF: *Practitioner 217*:804-809, Nov 1976. 4. Antibiotic Sensitivity Report, Winter 1983. BAC-DATA Medical Information Systems, Inc. 5. Data on file, Hoffmann-La Roche Inc., Nutley, NJ. 6. Wormser GP, Keusch GT, Heel RC: *Drugs 24*:459-518, Dec 1982. 7. *Med Lett Drugs Ther 23*:93-95, Oct 30, 1981.

BACTRIM™ (trimethoprim and sulfamethoxazole/Roche)

Before prescribing, please consult complete product information, a summary of which follows:
Indications and Usage: For the treatment of urinary tract infections due to susceptible strains of the following organisms: *Escherichia coli, Klebsiella-Enterobacter, Proteus mirabilis, Proteus vulgaris, Proteus morganii*. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. *Note:* The increasing frequency of resistant organisms limits the usefulness of all antibacterials, especially in these urinary tract infections.
For acute otitis media in children due to susceptible strains of *Haemophilus influenzae* or *Streptococcus pneumoniae* when in physician's judgment it offers an advantage over other antimicrobials. To date, there are limited data on the safety of repeated use of Bactrim in children under two years of age. Bactrim is not indicated for prophylactic or prolonged administration in otitis media at any age.
For acute exacerbations of chronic bronchitis in adults due to susceptible strains of *Haemophilus influenzae* or *Streptococcus pneumoniae* when in physician's judgment it offers an advantage over a single antimicrobial agent.
For enteritis due to susceptible strains of *Shigella flexneri* and *Shigella sonnei* when antibacterial therapy is indicated.
Also for the treatment of documented *Pneumocystis carinii* pneumonitis.
Contraindications: Hypersensitivity to trimethoprim or sulfonamides; patients with documented megaloblastic anemia due to folate deficiency; pregnancy at term; nursing mothers because sulfonamides are excreted in human milk and may cause kernicterus; infants less than 2 months of age.
Warnings: BACTRIM SHOULD NOT BE USED TO TREAT STREPTOCOCCAL PHARYNGITIS. Clinical studies show that patients with group A β-hemolytic streptococcal tonsillopharyngitis have higher incidence of bacteriologic failure when treated with Bactrim than do those treated with penicillin. Deaths from hypersensitivity reactions, hepatocellular necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias have been associated with sulfonamides. Experience with trimethoprim is much more limited but occasional interference with hematopoiesis has been reported as well as an increased incidence of thrombopenia with purpura in elderly patients on certain diuretics, primarily thiazides. Sore throat, fever, pallor, purpura or jaundice may be early signs of serious blood disorders. Frequent CBC's are recommended; therapy should be discontinued if a significantly reduced count of any formed blood element is noted.
Precautions: *General:* Use cautiously in patients with impaired renal or hepatic function, possible folate deficiency, severe allergy or bronchial asthma. In patients with glucose-6-phosphate dehydrogenase deficiency, hemolysis, frequently dose-related, may occur. During therapy, maintain adequate fluid intake and perform frequent urinalyses, with careful microscopic examination, and renal function tests, particularly where there is impaired renal function. Bactrim may prolong prothrombin time in those receiving warfarin; reassess coagulation time when administering Bactrim to these patients.
Pregnancy: Teratogenic Effects: Pregnancy Category C. Because trimethoprim and sulfamethoxazole may interfere with folic acid metabolism, use during pregnancy only if potential benefits justify the potential risk to the fetus.
Adverse Reactions: All major reactions to sulfonamides and trimethoprim are included, even if not reported with Bactrim. *Blood dyscrasias:* Agranulocytosis, aplastic anemia, megaloblastic anemia, thrombopenia, leukopenia, hemolytic anemia, purpura, hypoprothrombinemia and methemoglobinemia. *Allergic reactions:* Erythema multiforme, Stevens-Johnson syndrome, generalized skin eruptions, epidermal necrolysis, urticaria, serum sickness, pruritus, exfoliative dermatitis, anaphylactoid reactions, periorbital edema, conjunctival and scleral injection, photosensitization, arthralgia and allergic myocarditis. *Gastrointestinal reactions:* Glossitis, stomatitis, nausea, emesis, abdominal pains, hepatitis, hepatocellular necrosis, diarrhea, pseudomembranous colitis and pancreatitis. *CNS reactions:* Headache, peripheral neuritis, mental depression, convulsions, ataxia, hallucinations, tinnitus, vertigo, insomnia, apathy, fatigue, muscle weakness and nervousness. *Miscellaneous reactions:* Drug fever, chills, toxic nephrosis with oliguria and anuria, periarteritis nodosa and L.E. phenomenon. Due to certain chemical similarities to some goitrogens, diuretics (acetazolamide, thiazides) and oral hypoglycemic agents, sulfonamides have caused rare instances of goiter production, diuresis and hypoglycemia in patients; cross-sensitivity with these agents may exist. In rats, long-term therapy with sulfonamides has produced thyroid malignancies.
Dosage: Not recommended for infants less than two months of age.
URINARY TRACT INFECTIONS AND SHIGELLOSIS IN ADULTS AND CHILDREN, AND ACUTE OTITIS MEDIA IN CHILDREN:
Adults: Usual adult dosage for urinary tract infections—1 DS tablet (double strength), 2 tablets (single strength) or 4 teasp. (20 ml) b.i.d. for 10-14 days. Use identical daily dosage for 5 days for shigellosis.
Children: Recommended dosage for children with urinary tract infections or acute otitis media—8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole per 24 hours, in two divided doses for 10 days. Use identical daily dosage for 5 days for shigellosis.
For patients with renal impairment: Use recommended dosage regimen when creatinine clearance is above 30 ml/min. If creatinine clearance is between 15 and 30 ml/min, use one-half the usual regimen. Bactrim is not recommended if creatinine clearance is below 15 ml/min.
ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS IN ADULTS:
Usual adult dosage: 1 DS tablet (double strength), 2 tablets (single strength) or 4 teasp. (20 ml) b.i.d. for 14 days.
PNEUMOCYSTIS CARINII PNEUMONITIS:
Recommended dosage: 20 mg/kg trimethoprim and 100 mg/kg sulfamethoxazole per 24 hours in equal doses every 6 hours for 14 days. See complete product information for suggested children's dosage table.
Supplied: *Double Strength (DS) tablets*, each containing 160 mg trimethoprim and 800 mg sulfamethoxazole, bottles of 100, 250 and 500; Tel-E-Dose® packages of 100; Prescription Paks of 20. *Tablets*, each containing 80 mg trimethoprim and 400 mg sulfamethoxazole—bottles of 100 and 500; Tel-E-Dose® packages of 100; Prescription Paks of 40. *Pediatric Suspension*, containing 40 mg trimethoprim and 200 mg sulfamethoxazole per teaspoonful (5 ml); cherry flavored—bottles of 100 ml and 16 oz (1 pint). *Suspension*, containing 40 mg trimethoprim and 200 mg sulfamethoxazole per teaspoonful (5 ml); fruit-licorice flavored—bottles of 16 oz (1 pint).

ROCHE LABORATORIES
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

INTERNISTS FAMILY PRACTITIONERS

FHP, a rapidly expanding multi-specialty group practice, has full time opportunities for residency trained, Board certified (or eligible) Internists and Family Practitioners. These Southern California positions offer a full range of in-hospital and outpatient responsibilities in a comprehensive care environment. Administrative opportunities are also available.

For more information, please write or call William Trainor, Manager of Professional Staffing, toll-free at 1-800-446-2255 (in California, call 1-800-336-2255).

FHP

Professional Staffing
9900 Talbert Avenue • P.O. Box 8000
Fountain Valley, California 92708-8000

The Western Journal of Medicine
(ISSN 0093-0415/USPS 084 480) is published monthly for $20 per year (USA and Canada) by the California Medical Association, P.O. Box 7602, San Francisco, CA 94120-7602. Second-class postage paid at San Francisco, CA and additional mailing offices.
POSTMASTER: Send address changes to *The Western Journal of Medicine*, Circulation, P.O. Box 7602, San Francisco, CA 94120-7602.

Moving?

Please give us six weeks notice and supply your personal reference number.

ID No.

The Western Journal of Medicine
P.O. Box 7602
San Francisco, CA 94120-7602.

302703 XX

The Western Journal of Medicine

P.O. Box 7602, San Francisco, CA 94120-7602

Before prescribing, see complete prescribing information in SK&F CO. literature or *PDR*. The following is a brief summary.

* **WARNING**

This drug is not indicated for initial therapy of edema or hypertension. Edema or hypertension requires therapy titrated to the individual. If this combination represents the dosage so determined, its use may be more convenient in patient management. Treatment of hypertension and edema is not static, but must be reevaluated as conditions in each patient warrant.

Contraindications: Concomitant use with other potassium-sparing agents such as spironolactone or amiloride. Further use in anuria, progressive renal or hepatic dysfunction, hyperkalemia. Pre-existing elevated serum potassium. Hypersensitivity to either component or other sulfonamide-derived drugs.

Warnings: Do not use potassium supplements, dietary or otherwise, unless hypokalemia develops or dietary intake of potassium is markedly impaired. If supplementary potassium is needed, potassium tablets should not be used. Hyperkalemia can occur, and has been associated with cardiac irregularities. It is more likely in the severely ill, with urine volume less than one liter/day, the elderly and diabetics with suspected or confirmed renal insufficiency. Periodically, serum K^+ levels should be determined. If hyperkalemia develops, substitute a thiazide alone, restrict K^+ intake. **Associated widened QRS complex or arrhythmia requires prompt additional therapy.** Thiazides cross the placental barrier and appear in cord blood. Use in pregnancy requires weighing anticipated benefits against possible hazards, including fetal or neonatal jaundice, thrombocytopenia, other adverse reactions seen in adults. Thiazides appear and triamterene may appear in breast milk. If their use is essential, the patient should stop nursing. Adequate information on use in children is not available. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. Possible exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics.

Precautions: The bioavailability of the hydrochlorothiazide component of 'Dyazide' is about 50% of the bioavailability of the single entity. Theoretically, a patient transferred from the single entities of Dyrenium (triamterene, SK&F CO.) and hydrochlorothiazide may show an increase in blood pressure or fluid retention. Similarly, it is also possible that the lesser hydrochlorothiazide bioavailability could lead to increased serum potassium levels. However, extensive clinical experience with 'Dyazide' suggests that these conditions have not been commonly observed in clinical practice. Do periodic serum electrolyte determinations (particularly important in patients vomiting excessively or receiving parenteral fluids, and during concurrent use with amphotericin B or corticosteroids or corticotropin [ACTH]). Periodic BUN and serum creatinine determinations should be made, especially in the elderly, diabetics or those with suspected or confirmed renal insufficiency. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate coma in patients with severe liver disease. Observe regularly for possible blood dyscrasias, liver damage, other idiosyncratic reactions. Blood dyscrasias have been reported in patients receiving triamterene, and leukopenia, thrombocytopenia, agranulocytosis, and aplastic and hemolytic anemia have been reported with thiazides. Thiazides may cause manifestation of latent diabetes mellitus. The effects of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary. Clinically insignificant reductions in arterial responsiveness to norepinephrine have been reported. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine. Triamterene is a weak folic acid antagonist. Do periodic blood studies in cirrhotics with splenomegaly. Antihypertensive effects may be enhanced in post-sympathectomy patients. Use cautiously in surgical patients. Triamterene has been found in renal stones in association with the other usual calculus components. Therefore, 'Dyazide' should be used with caution in patients with histories of stone formation. A few occurrences of acute renal failure have been reported in patients on 'Dyazide' when treated with indomethacin. Therefore, caution is advised in administering nonsteroidal anti-inflammatory agents with 'Dyazide'. The following may occur: transient elevated BUN or creatinine or both, hyperglycemia and glycosuria (diabetic insulin requirements may be altered), hyperuricemia and gout, digitalis intoxication (in hypokalemia), decreasing alkali reserve with possible metabolic acidosis. 'Dyazide' interferes with fluorescent measurement of quinidine. Hypokalemia is uncommon with 'Dyazide', but should it develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods. Corrective measures should be instituted cautiously and serum potassium levels determined. Discontinue corrective measures and 'Dyazide' should laboratory values reveal elevated serum potassium. Chloride deficit may occur as well as dilutional hyponatremia. Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. Serum PBI levels may decrease without signs of thyroid disturbance. Calcium excretion is decreased by thiazides. 'Dyazide' should be withdrawn before conducting tests for parathyroid function.

Thiazides may add to or potentiate the action of other antihypertensive drugs.

Diuretics reduce renal clearance of lithium and increase the risk of lithium toxicity.

Adverse Reactions: Muscle cramps, weakness, dizziness, headache, dry mouth; anaphylaxis, rash, urticaria, photosensitivity, purpura, other dermatological conditions; nausea and vomiting, diarrhea, constipation, other gastrointestinal disturbances; postural hypotension (may be aggravated by alcohol, barbiturates, or narcotics). Necrotizing vasculitis, paresthesias, icterus, pancreatitis, xanthopsia and respiratory distress including pneumonitis and pulmonary edema, transient blurred vision, sialadenitis, and vertigo have occurred with thiazides alone. Triamterene has been found in renal stones in association with other usual calculus components. Rare incidents of acute interstitial nephritis have been reported. Impotence has been reported in a few patients on 'Dyazide', although a causal relationship has not been established.

Supplied: 'Dyazide' is supplied as a red and white capsule, in bottles of 1000 capsules; Single Unit Packages (unit-dose) of 100 (intended for institutional use only); in Patient-Pak™ unit-of-use bottles of 100.

BRS-DZ:L39

a product of

SK&F CO.

Carolina, P.R. 00630

©SK&F Co., 1985

The unique red and white Dyazide® capsule: Your assurance of SK&F quality.

In Hypertensives Over 50, Diuretics Are Preferred

The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommends diuretics as the favored monotherapy in patients over 50 years of age, regardless of sex or race.

Beta Blockers Aren't for Everyone...

For Hypertensive Patients*Over 50

P R E S C R I B E

®

25 mg Hydrochlorothiazide/**50 mg** Triamterene/SKF

Used with Confidence for over 19 Years

Serum K^+ and BUN should be checked periodically (see Warnings and Precautions).


Motrin® 800
ibuprofen

Extra strength
Convenience
Economy

Upjohn 100 A Century of Caring 1886·1986

© 1986 The Upjohn Company

J-6138 January 1986

COMING SOON

FROM Glaxo/ROCHE



Zantac® 300

ranitidine HCl/Glaxo 300 mg tablets

© 1986, Glaxo Inc. ZAN292 January 1986

BALANCED CALCIUM CHANNEL BLOCKER


CARDIZEM
(diltiazem HCl)
balances potent coronary vasodilation with a low incidence of side effects

Low incidence of side effects
CARDIZEM® (diltiazem HCl) produces an incidence of adverse reactions not greater than that reported with placebo therapy, thus contributing to the patient's sense of well-being.

*Cardizem is indicated in the treatment of angina pectoris due to coronary artery spasm and in the management of chronic stable angina (classic effort-associated angina) in patients who cannot tolerate therapy with beta-blockers and/or nitrates or who remain symptomatic despite adequate doses of these agents.

References:

1. [illegible] WE, McIntyre KM, Parisi AF, et al: Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris. Report of a cooperative clinical trial: Am J Cardiol [illegible], 1982.
2. [illegible] PE, Seagren SC, Bonanno JA, et al: The treatment of exercise-[illegible] chronic stable angina with diltiazem. Effect on treadmill [illegible]. Chest 78 (July suppl): 234-236, 1980.

Reduces angina attack frequency*
42% to 46% decrease reported in multicenter study.[1]

Increases exercise tolerance*
In Bruce exercise test,[2] control patients averaged 8.0 minutes to onset of pain; Cardizem patients averaged 9.8 minutes ($P<.005$).

CARDIZEM®
(diltiazem HCl)

THE BALANCED CALCIUM CHANNEL BLOCKER

Please see full prescribing information on following page.

2/84

PROFESSIONAL USE INFORMATION

cardizem®
(diltiazem HCl)
30 mg and 60 mg tablets

DESCRIPTION

CARDIZEM® (diltiazem hydrochloride) is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1,5-Benzothiazepin-4(5H)one,3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+)-cis-. The chemical structure is:



Diltiazem hydrochloride is a white to off-white crystalline powder with a bitter taste. It is soluble in water, methanol, and chloroform. It has a molecular weight of 450.98. Each tablet of CARDIZEM contains either 30 mg or 60 mg diltiazem hydrochloride for oral administration.

CLINICAL PHARMACOLOGY

The therapeutic benefits achieved with CARDIZEM are believed to be related to its ability to inhibit the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle.

Mechanisms of Action. Although precise mechanisms of its antianginal actions are still being delineated, CARDIZEM is believed to act in the following ways:

1. Angina Due to Coronary Artery Spasm: CARDIZEM has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasm are inhibited by CARDIZEM.
2. Exertional Angina: CARDIZEM has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic blood pressure at submaximal and maximal exercise work loads.

In animal models, diltiazem interferes with the slow inward (depolarizing) current in excitable tissue. It causes excitation-contraction uncoupling in various myocardial tissues without changes in the configuration of the action potential. Diltiazem produces relaxation of coronary vascular smooth muscle and dilation of both large and small coronary arteries at drug levels which cause little or no negative inotropic effect. The resultant increases in coronary blood flow (epicardial and subendocardial) occur in ischemic and nonischemic models and are accompanied by dose-dependent decreases in systemic blood pressure and decreases in peripheral resistance.

Hemodynamic and Electrophysiologic Effects. Like other calcium antagonists, diltiazem decreases sinoatrial and atrioventricular conduction in isolated tissues and has a negative inotropic effect in isolated preparations. In the intact animal, prolongation of the AH interval can be seen at higher doses.

In man, diltiazem prevents spontaneous and ergonovine-provoked coronary artery spasm. It causes a decrease in peripheral vascular resistance and a modest fall in blood pressure and, in exercise tolerance studies in patients with ischemic heart disease, reduces the heart rate-blood pressure product for any given work load. Studies to date, primarily in patients with good ventricular function, have not revealed evidence of a negative inotropic effect; cardiac output, ejection fraction, and left ventricular end diastolic pressure have not been affected. There are as yet few data on the interaction of diltiazem and beta-blockers. Resting heart rate is usually unchanged or slightly reduced by diltiazem.

Intravenous diltiazem in doses of 20 mg prolongs AH conduction time and AV node functional and effective refractory periods approximately 20%. In a study involving single oral doses of 300 mg of CARDIZEM in six normal volunteers, the average maximum PR prolongation was 14% with no instances of greater than first-degree AV block. Diltiazem-associated prolongation of the AH interval is not more pronounced in patients with first-degree heart block. In patients with sick sinus syndrome, diltiazem significantly prolongs sinus cycle length (up to 50% in some cases).

Chronic oral administration of CARDIZEM in doses of up to 240 mg/day has resulted in small increases in PR interval, but has not usually produced abnormal prolongation. There were, however, three instances of second-degree AV block and one instance of third-degree AV block in a group of 959 chronically treated patients.

Pharmacokinetics and Metabolism. Diltiazem is absorbed from the tablet formulation to about 80% of a reference capsule and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%. CARDIZEM undergoes extensive hepatic metabolism in which 2% to 4% of the unchanged drug appears in the urine. In vitro binding studies show CARDIZEM is 70% to 80% bound to plasma proteins. Competitive ligand binding studies have also shown CARDIZEM binding is not altered by therapeutic concentrations of digoxin, hydrochlorothiazide, phenylbutazone, propranolol, salicylic acid, or warfarin. Single oral doses of 30 to 120 mg of CARDIZEM result in detectable plasma levels within 30 to 60 minutes and peak plasma levels two to three hours after drug administration. The plasma elimination half-life following single or multiple drug administration is approximately 3.5 hours. Desacetyl diltiazem is also present in the plasma at levels of 10% to 20% of the parent drug and is 25% to 50% as potent a coronary vasodilator as diltiazem. Therapeutic blood levels of CARDIZEM appear to be in the range of 50 to 200 ng/ml. There is a departure from dose-linearity when single doses above 60 mg are given; a 120-mg dose gave blood levels three times that of the 60-mg dose. There is no information about the effect of renal or hepatic impairment on excretion or metabolism of diltiazem.

INDICATIONS AND USAGE

1. **Angina Pectoris Due to Coronary Artery Spasm.** CARDIZEM is indicated in the treatment of angina pectoris due to coronary artery spasm. CARDIZEM has been shown effective in the treatment of spontaneous coronary artery spasm presenting as Prinzmetal's variant angina (resting angina with ST-segment elevation occurring during attacks).
2. **Chronic Stable Angina (Classic Effort-Associated Angina).** CARDIZEM is indicated in the management of chronic stable angina. CARDIZEM has been effective in controlled trials in reducing angina frequency and increasing exercise tolerance.

There are no controlled studies of the effectiveness of the concomitant use of diltiazem and beta-blockers or of the safety of this combination in patients with impaired ventricular function or conduction abnormalities.

CONTRAINDICATIONS

CARDIZEM is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker, and (3) patients with hypotension (less than 90 mm Hg systolic).

WARNINGS

1. **Cardiac Conduction.** CARDIZEM prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (six of 1243 patients for 0.48%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem.
2. **Congestive Heart Failure.** Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). Experience with the use of CARDIZEM alone or in combination with beta-blockers in patients with impaired ventricular function is very limited. Caution should be exercised when using the drug in such patients.
3. **Hypotension.** Decreases in blood pressure associated with CARDIZEM therapy may occasionally result in symptomatic hypotension.
4. **Acute Hepatic Injury.** In rare instances, patients receiving CARDIZEM have exhibited reversible acute hepatic injury as evidenced by moderate to extreme elevations of liver enzymes. (See PRECAUTIONS and ADVERSE REACTIONS.)

PRECAUTIONS

General. CARDIZEM (diltiazem hydrochloride) is extensively metabolized by the liver and excreted by the kidneys and in bile. As with any new drug given over prolonged periods, laboratory parameters should be monitored at regular intervals. The drug should be used with caution in patients with impaired renal or hepatic function. In subacute and chronic dog and rat studies designed to produce toxicity, high doses of diltiazem were associated with hepatic damage. In special subacute hepatic studies, oral doses of 125 mg/kg and higher in rats were associated with histological changes in the liver which were reversible when the drug was discontinued. In dogs, doses of 20 mg/kg were also associated with hepatic changes; however, these changes were reversible with continued dosing.

Drug Interaction. Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM. (See WARNINGS).

Controlled and uncontrolled domestic studies suggest that concomitant use of CARDIZEM and beta-blockers or digitalis is usually well tolerated. Available data are not sufficient, however, to predict the effects of concomitant treatment, particularly in patients with left ventricular dysfunction or cardiac conduction abnormalities. In healthy volunteers, diltiazem has been shown to increase serum digoxin levels up to 20%.

Carcinogenesis, Mutagenesis, Impairment of Fertility. A 24-month study in rats and a 21-month study in mice showed no evidence of carcinogenicity. There was also no mutagenic response in in vitro bacterial tests. No intrinsic effect on fertility was observed in rats.

Pregnancy. Category C. Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from five to ten times greater (on a mg/kg basis) than the daily recommended therapeutic dose has resulted in embryo and fetal lethality. These doses, in some studies, have been reported to cause skeletal abnormalities. In the perinatal/postnatal studies, there was some reduction in early individual pup weights and survival rates. There was an increased incidence of stillbirths at doses of 20 times the human dose or greater.

There are no well-controlled studies in pregnant women; therefore, use CARDIZEM in pregnant women only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when CARDIZEM is administered to a nursing woman if the drug's benefits are thought to outweigh its potential risks in this situation.

Pediatric Use. Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded.

In domestic placebo-controlled trials, the incidence of adverse reactions reported during CARDIZEM therapy was not greater than that reported during placebo therapy.

The following represent occurrences observed in clinical studies which can be at least reasonably associated with the pharmacology of calcium influx inhibition. In many cases, the relationship to CARDIZEM has not been established. The most common occurrences, as well as their frequency of presentation, are: edema (2.4%), headache (2.1%), nausea (1.9%), dizziness (1.5%), rash (1.3%), asthenia (1.2%), AV block (1.1%). In addition, the following events were reported infrequently (less than 1%) with the order of presentation corresponding to the relative frequency of occurrence.

Cardiovascular:	Flushing, arrhythmia, hypotension, bradycardia, palpitations, congestive heart failure, syncope.
Nervous System:	Paresthesia, nervousness, somnolence, tremor, insomnia, hallucinations, and amnesia.
Gastrointestinal:	Constipation, dyspepsia, diarrhea, vomiting, mild elevations of alkaline phosphatase, SGOT, SGPT, and LDH.
Dermatologic:	Pruritus, petechiae, urticaria, photosensitivity.
Other:	Polyuria, nocturia.

The following additional experiences have been noted:

A patient with Prinzmetal's angina experiencing episodes of vasospastic angina developed periods of transient asymptomatic asystole approximately five hours after receiving a single 60-mg dose of CARDIZEM.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM: erythema multiforme; leukopenia; and extreme elevations of alkaline phosphatase, SGOT, SGPT, LDH, and CPK. However, a definitive cause and effect between these events and CARDIZEM therapy is yet to be established.

OVERDOSAGE OR EXAGGERATED RESPONSE

Overdosage experience with oral diltiazem has been limited. Single oral doses of 300 mg of CARDIZEM have been well tolerated by healthy volunteers. In the event of overdosage or exaggerated response, appropriate supportive measures should be employed in addition to gastric lavage. The following measures may be considered:

Bradycardia	Administer atropine (0.60 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.
High-Degree AV Block	Treat as for bradycardia above. Fixed high-degree AV block should be treated with cardiac pacing.
Cardiac Failure	Administer inotropic agents (isoproterenol, dopamine, or dobutamine) and diuretics.
Hypotension	Vasopressors (eg, dopamine or levarterenol bitartrate).

Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician.

The oral/LD_{50}'s in mice and rats range from 415 to 740 mg/kg and from 560 to 810 mg/kg, respectively. The intravenous LD_{50}'s in these species were 60 and 38 mg/kg, respectively. The oral LD_{50} in dogs is considered to be in excess of 50 mg/kg, while lethality was seen in monkeys at 360 mg/kg. The toxic dose in man is not known, but blood levels in excess of 800 ng/ml have not been associated with toxicity.

DOSAGE AND ADMINISTRATION

Exertional Angina Pectoris Due to Atherosclerotic Coronary Artery Disease or Angina Pectoris at Rest Due to Coronary Artery Spasm. Dosage must be adjusted to each patient's needs. Starting with 30 mg four times daily, before meals and at bedtime, dosage should be increased gradually (given in divided doses three or four times daily) at one- to two-day intervals until optimum response is obtained. Although individual patients may respond to any dosage level, the average optimum dosage range appears to be 180 to 240 mg/day. There are no available data concerning dosage requirements in patients with impaired renal or hepatic function. If the drug must be used in such patients, titration should be carried out with particular caution.

Concomitant Use With Other Antianginal Agents:

1. **Sublingual NTG** may be taken as required to abort acute anginal attacks during CARDIZEM therapy.
2. **Prophylactic Nitrate Therapy**—CARDIZEM may be safely coadministered with short- and long-acting nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
3. **Beta-blockers.** (See WARNINGS and PRECAUTIONS.)

HOW SUPPLIED

Cardizem 30-mg tablets are supplied in bottles of 100 (NDC 0088-1771-47) and in Unit Dose Identification Paks of 100 (NDC 0088-1771-49). Each green tablet is engraved with MARION on one side and 1771 engraved on the other. CARDIZEM 60-mg scored tablets are supplied in bottles of 100 (NDC 0088-1772-47) and in Unit Dose Identification Paks of 100 (NDC 0088-1772-49). Each yellow tablet is engraved with MARION on one side and 1772 on the other.

Issued 4/1/84

Another patient benefit product from

PHARMACEUTICAL DIVISION
MARION LABORATORIES, INC.
KANSAS CITY, MISSOURI 64137

"With [CAPOTEN®(captopril tablets)] it appears that for the first time ever a patient can feel as well on treatment for high blood pressure as he does off it."[1]

*Angiotensin Converting Enzyme

†**CAPOTEN may be used as initial therapy only for patients with normal renal function in whom the risk of neutropenia/agranulocytosis is relatively low (1 out of over 8,600 in clinical trials). Use special precautions in patients with impaired renal function, collagen vascular disorders, or those exposed to other drugs known to affect the white cells or immune response. Evaluation of hypertensives should always include assessment of renal function. See INDICATIONS AND USAGE, WARNINGS, and ADVERSE REACTIONS in the brief summary on the adjacent page.**

‡**The most frequently occurring adverse reactions are skin rash and taste alteration; both effects are generally mild, reversible, or self-limited.**

Reference:

1. Stumpe KO, Overlack A, Kolloch R, et al: Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension. Br J Clin Pharmacol 14(suppl 2):121S-126S, 1982.

Expanded Prescribing Freedom–
Mild-to-Moderate Hypertension

Capoten for Initial Therapy of Hypertension†



- ☐ Fatigue, loss of libido, impotence, and mental impairment almost never occur‡
- ☐ Effective alone or in combination with diuretics
- ☐ Convenient bid dosage

ACE*INHIBITOR

CAPOTEN®
captopril tablets

FIRST-LINE THERAPY THAT PUTS QUALITY OF LIFE FIRST

SQUIBB®

CAPOTEN® TABLETS
Captopril Tablets

INDICATIONS: Hypertension – CAPOTEN (captopril) is indicated for the treatment of hypertension. Consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for those who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics.

Heart Failure: CAPOTEN (captopril) is indicated in patients with heart failure who have not responded adequately to or cannot be controlled by conventional diuretic and digitalis therapy. CAPOTEN is to be used with diuretics and digitalis.

WARNINGS: Neutropenia/Agranulocytosis – Neutropenia (<1000/mm³) with myeloid hypoplasia has resulted from use of captopril. About half of the neutropenic patients developed systemic or oral cavity infections or other features of the syndrome of agranulocytosis. The risk of neutropenia is dependent on the clinical status of the patient:

In clinical trials in patients with hypertension who have normal renal function (serum creatinine <1.6 mg/dL and no collagen vascular disease), neutropenia has been seen in one patient out of over 8,600 exposed. In patients with some degree of renal failure (serum creatinine at least 1.6 mg/dL) but no collagen vascular disease, the risk in clinical trials was about 1 per 500. Doses were relatively high in these patients, particularly in view of their diminished renal function. In patients with collagen vascular diseases (e.g., systemic lupus erythematosus, scleroderma) and impaired renal function, neutropenia occurred in 3.7% of patients in clinical trials. While none of the over 750 patients in formal clinical trials of heart failure developed neutropenia, it has occurred during subsequent clinical experience. Of reported cases, about half had serum creatinine ≥1.6 mg/dL and more than 75% received procainamide. In heart failure, it appears that the same risk factors for neutropenia are present.

Neutropenia has appeared usually within 3 months after starting therapy, associated with myeloid hypoplasia and frequently accompanied by erythroid hypoplasia and decreased numbers of megakaryocytes (e.g., hypoplastic bone marrow and pancytopenia); anemia and thrombocytopenia were sometimes seen. Neutrophils generally returned to normal in about 2 weeks after captopril was discontinued, and serious infections were limited to clinically complex patients. About 13% of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors.

Evaluation of the hypertensive or heart failure patient should always include assessment of renal function. If captopril is used in patients with impaired renal function, white blood cell and differential counts should be evaluated prior to starting treatment and at approximately 2-week intervals for about 3 months, then periodically. In patients with collagen vascular disease or who are exposed to other drugs known to affect the white cells or immune response, particularly when there is impaired renal function, captopril should be used only after an assessment of benefit and risk, and then with caution. All patients treated with captopril should be told to report any signs of infection (e.g., sore throat, fever); if infection is suspected, perform counts without delay. Since discontinuation of captopril and other drugs has generally led to prompt return of the white count to normal, upon confirmation of neutropenia (neutrophil count <1000/mm³) withdraw captopril and closely follow the patient's course.

Proteinuria – Total urinary proteins >1 g/day were seen in about 0.7% of patients on captopril. About 90% of affected patients had evidence of prior renal disease or received high doses (>150 mg/day), or both. The nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within 6 months whether or not captopril was continued. The BUN and creatinine were seldom altered in proteinuric patients. Since most cases of proteinuria occurred by the 8th month of therapy, patients with prior renal disease or those receiving captopril at doses >150 mg/day should have urinary protein estimates (dip-stick on 1st morning urine) before therapy, and periodically thereafter.

Hypotension – Excessive hypotension was rarely seen in hypertensive patients but is a possibility in severely salt/volume-depleted persons such as those treated vigorously with diuretics (see PRECAUTIONS [Drug Interactions]).

In heart failure, where blood pressure was either normal or low, transient decreases in mean blood pressure >20% were recorded in about half of the patients. This transient hypotension may occur after any of the first several doses and is usually well tolerated, although rarely it has been associated with arrhythmia or conduction defects. A starting dose of 6.25 or 12.5 mg tid may minimize the hypotensive effect. Patients should be followed closely for the first 2 weeks of treatment and whenever the dose of captopril and/or diuretic is increased.

BECAUSE OF THE POTENTIAL FALL IN BLOOD PRESSURE IN THESE PATIENTS, THERAPY SHOULD BE STARTED UNDER VERY CLOSE MEDICAL SUPERVISION.

PRECAUTIONS: General: *Impaired Renal Function,* Hypertension – Some hypertensive patients with renal disease, particularly those with severe renal artery stenosis, have developed increases in BUN and serum creatinine. It may be necessary to reduce captopril dosage and/or discontinue diuretic. For some of these patients, normalization of blood pressure and maintenance of adequate renal perfusion may not be possible. Heart Failure – About 20% of patients develop stable elevations of BUN and serum creatinine >20% above normal or baseline upon long-term treatment. Less than 5% of patients, generally with severe preexisting renal disease, required discontinuation due to progressively increasing creatinine. See DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS [Altered Laboratory Findings]. *Valvular Stenosis* – A theoretical concern, for risk of decreased coronary perfusion, has been noted regarding vasodilator treatment in patients with aortic stenosis due to decreased afterload reduction.

Surgery/Anesthesia – If hypotension occurs during major surgery or anesthesia, and is considered due to the effects of captopril, it is correctable by volume expansion.

Drug Interactions: *Hypotension: Patients on Diuretic Therapy* – Precipitous reduction of blood pressure may occasionally occur within the 1st hour after administration of the initial captopril dose in patients on diuretics, especially those recently placed on diuretics, and those on severe dietary salt restriction or dialysis. This possibility can be minimized by either discontinuing the diuretic or increasing the salt intake about 1 week prior to initiation of captopril therapy or by initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least 1 hour after the initial dose.

Agents Having Vasodilator Activity – In heart failure patients, vasodilators should be administered with caution.

Agents Causing Renin Release – Captopril's effect will be augmented by antihypertensive agents that cause renin release.

Agents Affecting Sympathetic Activity – The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive. Therefore, use agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) with caution.

Agents Increasing Serum Potassium – Give potassium-sparing diuretics or potassium supplements only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Use potassium-containing salt substitutes with caution.

Inhibitors of Endogenous Prostaglandin Synthesis – Indomethacin and other nonsteroidal anti-inflammatory agents may reduce the antihypertensive effect of captopril, especially in low renin hypertension.

Drug/Laboratory Test Interaction: Captopril may cause a false-positive urine test for acetone.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Two-year studies with doses of 50 to 1350 mg/kg/day in mice and rats failed to show any evidence of carcinogenic potential. Studies in rats have revealed no impairment of fertility.

Pregnancy: Category C – There are no adequate and well-controlled studies in pregnant women. Embryocidal effects and craniofacial malformations were observed in rabbits. Therefore, captopril should be used during pregnancy, or for patients likely to become pregnant, only if the potential benefit outweighs the potential risk to the fetus. Captopril crosses the human placenta.

Nursing Mothers: Captopril is secreted in human milk. Exercise caution when administering captopril to a nursing woman, and, in general, nursing should be interrupted.

Pediatric Use: Safety and effectiveness in children have not been established although there is limited experience with use of captopril in children from 2 months to 15 years of age. Dosage, on a weight basis, was comparable to that used in adults. Captopril should be used in children only if other measures for controlling blood pressure have not been effective.

ADVERSE REACTIONS: Reported incidences are based on clinical trials involving approximately 7000 patients.

Renal – About 1 of 100 patients developed proteinuria (see WARNINGS). Renal insufficiency, renal failure, polyuria, oliguria, and urinary frequency in 1 to 2 of 1000 patients.

Hematologic – Neutropenia/agranulocytosis have occurred (see WARNINGS). Anemia, thrombocytopenia, and pancytopenia have been reported.

Dermatologic – Rash (usually maculopapular, rarely urticarial), often with pruritus and sometimes with fever and eosinophilia, in about 4 to 7 of 100 patients (depending on renal status and dose), usually during the 1st 4 weeks of therapy. Pruritus, without rash, in about 2 of 100 patients. A reversible associated pemphigoid-like lesion, and photosensitivity have also been reported. Angioedema of the face, mucous membranes of the mouth, or of the extremities in about 1 of 1000 patients – reversible on discontinuance of captopril therapy. One case of laryngeal edema reported. Flushing or pallor in 2 to 5 of 1000 patients.

Cardiovascular – Hypotension may occur, see WARNINGS and PRECAUTIONS (Drug Interactions) for discussion of hypotension on initiation of captopril therapy. Tachycardia, chest pain, and palpitations each in about 1 of 100 patients. Angina pectoris, myocardial infarction, Raynaud's syndrome, and congestive heart failure each in 2 to 3 of 1000 patients.

Dysgeusia – About 2 to 4 (depending on renal status and dose) of 100 patients developed a diminution or loss of taste perception; taste impairment is reversible and usually self-limited even with continued drug use (2 to 3 months). Gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, aphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, cough, alopecia, and paresthesias reported in about 0.5 to 2% of patients but did not appear at increased frequency compared to placebo or other treatments used in controlled trials.

Altered Laboratory Findings: Elevations of liver enzymes in a few patients although no causal relationship has been established. Rarely cholestatic jaundice and hepatocellular injury with or without secondary cholestasis, have been reported. A transient elevation of BUN and serum creatinine may occur, especially in volume-depleted or renovascular hypertensive patients. In instances of rapid reduction of longstanding or severely elevated blood pressure, the glomerular filtration rate may decrease transiently, also resulting in transient rises in serum creatinine and BUN. Small increases in serum potassium concentration frequently occur, especially in patients with renal impairment (see PRECAUTIONS).

OVERDOSAGE: Primary concern is correction of hypotension. Volume expansion with an I.V. infusion of normal saline is the treatment of choice for restoration of blood pressure. Captopril may be removed from the general circulation by hemodialysis.

DOSAGE AND ADMINISTRATION: CAPOTEN (captopril) should be taken one hour before meals. In hypertension, CAPOTEN may be dosed bid or tid. Dosage must be individualized; see DOSAGE AND ADMINISTRATION section of package insert for detailed information regarding dosage in hypertension and in heart failure. Because CAPOTEN (captopril) is excreted primarily by the kidneys, dosage adjustments are recommended for patients with impaired renal function.

Consult package insert before prescribing CAPOTEN (captopril).

HOW SUPPLIED: Available in tablets of 12.5, 25, 50, and 100 mg in bottles of 100 (25 mg also available in bottles of 1000), and in UNIMATIC® single dose packs of 100 tablets. (J3-658D)

SQUIBB®

INNOVATORS IN CARDIOVASCULAR MEDICINE

© 1986 E. R. Squibb & Sons, Inc., Princeton, NJ 08540 526-555 Issued: January 1986

11:00 p.m.

Time. It seems as though we never have enough. Just when you thought you'd caught up with paperwork, it's one more late night.

You'd always figured on early mornings and caring for patients. You knew people would need you in the middle of the night. That's medicine. But you had not figured on late nights taking care of your practice.

If you spend too much time on business—maybe more than on medicine—we can help. We're here to ease some of your office's administrative burden. We're Professional Office Business Systems from Blue Cross of California.

We have a physician-designed practice management system to handle virtually all of your office paperwork. The system automates insurance filings, and it will eliminate paper by permitting electronic submission of Blue Cross and Medicare claims.

The practice management system handles a large and expanding list of office functions: accounts receivable management, patient and insurance billing, customized statistical reporting, accounts payable, patient scheduling, general ledger and word processing.

Automation can eliminate many of the tedious and redundant tasks that take up much of your valuable staff time.

If time is a problem and taking away from your medicine, call us. We can help.

Professional Office Business Systems

a Blue Cross of California Company

(415) 645-3100

For Northern California
Doctors Only



© 1985, Pfizer Inc.

When the pain and inflammation of arthritis flare up...

- FELDENE is an [illegible] osteoarthritis and [illegible] arthritis. Beginning with the [illegible] FELDENE provides effective [illegible] relief of arthritis pain and stiffness.[1]
- Convenient once-daily dosage provides round-the-clock relief of symptoms[2]—encouraging compliance and enhancing productivity at home and on the job.[3]

Feldene®
(PIROXICAM) 20 mg capsules



Please see a brief summary of FELDENE (piroxicam) prescribing information on the following page.

Start one-a-day

Feldene

For full anti-arthritic action



Pfizer LABORATORIES DIVISION

DAN JOHNSON'S Office Blood Pressure is **153/92.**
Should he be Treated for Hypertension?

24 HOUR AMBULATORY BLOOD PRESSURE MONITORING RESOLVES THIS PROBLEM.



HYPERTENSION SCANNING SERVICE CAN PROVIDE YOU WITH THIS NEW TECHNOLOGY, WITH NO INVESTMENT REQUIRED.

Please see us at the
CMA Convention 2-28 thru 3-2
Bonaventure Hotel Booth 711

(800) 233-7959
(213) 452-7959

Hypertension Scanning Service, Inc.

CALIFORNIA DOCTORS ONLY

Center Stage

KEYNOTE SPEAKER

STEPHEN BARRETT, MD
Allentown, Pennsylvania

Consumer Advocate, Coauthor, *Consumer Health — A Guide to Intelligent Decisions* and *Vitamins & "Health" Foods: The Great American Hustle*

THE GROWING THREAT OF QUACKERY
Sunday, March 2 - 4:30 p.m.

GOLDEN APPLE AWARD

VICTOR D. NEWCOMER, MD
Santa Monica, California

Distinguished physician-teacher and recipient of CMA's first Golden Apple Award.

AGING SKIN
Sunday, March 2 - 12:00 p.m.



to CONTROL, COMPLIANCE, CONVENIENCE in HYPERTENSION

Corzide simplifies prescribing a beta-blocker plus a thiazide with reliable once-a-day dosing in a single tablet.



CORZIDE®

(nadolol-bendroflumethiazide tablets)

Makes good sense

*Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The 1984 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 144:1045-1057, 1984.

Please see brief summary on adjacent page.

CORZIDE®

(nadolol-bendroflumethiazide tablets)

CORZIDE® 40/5
CORZIDE® 80/5
Nadolol-Bendroflumethiazide Tablets

DESCRIPTION: CORZIDE (Nadolol-Bendroflumethiazide Tablets) for oral administration combines two antihypertensive agents: CORGARD® (nadolol), a nonselective beta-adrenergic blocking agent, and NATURETIN® (bendroflumethiazide), a thiazide diuretic-antihypertensive. Formulations: 40 mg and 80 mg nadolol per tablet combined with 5 mg bendroflumethiazide.

CONTRAINDICATIONS: Nadolol — Bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see WARNINGS). **Bendroflumethiazide** — Anuria, and in those with previous hypersensitivity to bendroflumethiazide or other sulfonamide-derived drugs.

WARNINGS: Nadolol — Cardiac Failure — Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle. IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta-blockers can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of heart failure, digitalize and/or give diuretics, and closely observe response, or discontinue nadolol (gradually, if possible).

> **Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal** — Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after *abrupt* discontinuation of such therapy. When discontinuing chronic use of nadolol, particularly in patients with ischemic heart disease, gradually reduce dosage over a 1- to 2-week period and carefully monitor the patient. Reinstitute nadolol promptly (at least temporarily) and take other measures appropriate for management of unstable angina if angina markedly worsens or acute coronary insufficiency develops. Warn patients not to interrupt or discontinue therapy without physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema) — PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS. Administer nadolol with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of $beta_2$ receptors. **Major Surgery** — Because beta blockade impairs the ability of the heart to respond to reflex stimuli and may increase the risks of general anesthesia and surgical procedures, resulting in protracted hypotension or low cardiac output, it has generally been suggested that such therapy should be withdrawn several days prior to surgery. Recognition of the increased sensitivity to catecholamines of patients recently withdrawn from beta-blocker therapy, however, has made this recommendation controversial. If possible, withdraw beta-blockers well before surgery takes place. In emergency surgery, inform the anesthesiologist that the patient is on beta-blocker therapy. Use of beta-receptor agonists such as isoproterenol, dopamine, dobutamine, or levarterenol can reverse the effects of nadolol. Difficulty in restarting and maintaining the heart beat has also been reported with beta-adrenergic receptor blocking agents. **Diabetes and Hypoglycemia** — Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust dose of antidiabetic drugs. **Thyrotoxicosis** — Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. To avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm, carefully manage patients suspected of developing thyrotoxicosis.

Bendroflumethiazide — Use with caution in severe renal disease. In patients with renal disease, azotemia may be precipitated. With impaired renal function, effects of the drug may be cumulative. Use with caution in impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Sensitivity reactions may occur in patients with a history of allergy or bronchial asthma. Possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

PRECAUTIONS: General — Nadolol — Use with caution in patients with impaired hepatic or renal function (see DOSAGE AND ADMINISTRATION).

Bendroflumethiazide — At appropriate intervals, perform serum electrolytes determination to detect possible electrolyte imbalance warning signs of which are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and G.I. disturbances such as nausea and vomiting. Observe patients for clinical signs of fluid or electrolyte imbalance; namely, hyponatremia, hypochloremic alkalosis, hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Drugs such as digitalis may influence serum electrolytes. Hypokalemia may develop, especially with brisk diuresis, in presence of severe cirrhosis. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Response of the heart to toxic effects of digitalis can be exaggerated with hypokalemia. Use potassium supplements such as high potassium foods to avoid or treat hypokalemia. Any chloride deficit is generally mild and usually does not require specific therapy except under extraordinary circumstances (as in liver or renal disease). Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than salt administration except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

Hyperuricemia may occur or frank gout may be precipitated in certain thiazide-treated patients. Latent diabetes mellitus may become manifest during thiazide therapy. Antihypertensive effects of bendroflumethiazide may be enhanced in the postsympathectomy patient.

Careful reappraisal of therapy and consideration given to withholding or stopping diuretic therapy is necessary if rising nonprotein nitrogen or BUN (indicative of progressive renal impairment) occurs. Thiazides may decrease serum PBI levels without signs of thyroid disturbance. Thiazides decrease calcium excretion. Pathologic changes in parathyroid gland with hypercalcemia and hypophosphatemia have been occasionally observed with prolonged therapy. Common complications of hyperparathyroidism have not been seen.

Information for Patients — Warn patients, especially those with evidence of coronary artery insufficiency, against interruption or discontinuation of nadolol without physician's advice. Although cardiac failure rarely occurs in properly selected patients, advise patients being treated with beta-adrenergic blocking agents to consult physician at the first sign or symptom of impending failure. Advise patients of proper course if dose inadvertently missed.

Laboratory Tests — Regularly monitor serum and urine electrolyte levels (see WARNINGS, *Bendroflumethiazide,* and PRECAUTIONS, *General, Bendroflumethiazide).*

Drug Interactions — **Nadolol** — When administered concurrently the following drugs may interact with beta-adrenergic blocking agents: **Anesthetics, general** — exaggeration of anesthetic-induced hypotension (see WARNINGS, *Nadolol, Major Surgery).* **Antidiabetic drugs (oral agents and insulin)** — hypoglycemia or hyperglycemia; adjust antidiabetic drug dosage accordingly (see WARNINGS, *Nadolol, Diabetes and Hypoglycemia).* **Catecholamine-depleting drugs (e.g., reserpine)** — additive effect; monitor closely for evidence of hypotension and/or excessive bradycardia.

Bendroflumethiazide — When administered concurrently the following drugs may interact with thiazide diuretics: **Alcohol, barbiturates, or narcotics** — may potentiate orthostatic hypotension. **Antidiabetic drugs (oral agents and insulin)** — thiazide-induced hyperglycemia may require adjustment of antidiabetic drug dosage. **Other antihypertensive drugs** — additive or potentiated effect. **Corticosteroids, ACTH** — intensified electrolyte depletion, particularly hypokalemia. **Ganglionic or peripheral adrenergic blocking drugs** — potentiated effect. **Preanesthetic and anesthetic agents** — effects may be potentiated; adjust dosage accordingly. **Pressor amines (e.g., norepinephrine)** — possible decrease response but not sufficient to preclude their use. **Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)** — possible increased response.

Drug/Laboratory Test Interactions — Discontinue thiazides before tests for parathyroid function (see PRECAUTIONS, *General, Bendroflumethiazide).*

Carcinogenesis, Mutagenesis, Impairment of Fertility — Nadolol — In 1 to 2 years oral toxicologic studies in mice, rats, and dogs, nadolol did not produce significant toxic effects. In 2-year oral carcinogenic studies in rats and mice, nadolol did not produce neoplastic, preneoplastic, or nonneoplastic pathologic lesions. **Bendroflumethiazide** — Long-term studies in animals have not been performed.

Pregnancy — **Teratogenic Effects** — **Nadolol** — Category C. In animal reproduction studies with nadolol, evidence of embryo- and fetotoxicity was found in rabbits, but not in rats or hamsters, at doses 5 to 10 times greater (on a mg/kg basis) than the maximum indicated human dose; no teratogenic potential was seen in any of these species. There are no well-controlled studies in pregnant women; therefore, use nadolol in pregnant women only if potential benefit justifies potential risk to the fetus. **Bendroflumethiazide** — Category C. Animal reproduction studies have not been conducted. This drug's effect on the fetus when administered to a pregnant woman or its effect on reproductive capacity is not known. Bendroflumethiazide should be given to a pregnant woman only if clearly needed. **Nonteratogenic Effects** — Since thiazides cross the placental barrier and appear in cord blood, weigh anticipated benefit of the drug in pregnant women against possible hazards to the fetus; these hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other reactions which have occurred in adults.

Nursing Mothers — Both nadolol and bendroflumethiazide are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants either discontinue nursing or discontinue therapy, taking into account the importance of CORZIDE (Nadolol-Bendroflumethiazide Tablets) to the mother.

Pediatric Use — Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: Nadolol — Most adverse effects have been mild and transient and have rarely required nadolol withdrawal. **Cardiovascular** — Bradycardia with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). **Central Nervous System** — Dizziness or fatigue reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior reported in approximately 6 of 1000 patients. **Respiratory** — Bronchospasm reported in approximately 1 of 1000 patients (see CONTRAINDICATIONS and WARNINGS). **Gastrointestinal** — Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating, and flatulence each reported in 1 to 5 of 1000 patients. **Miscellaneous** — Each of the following reported in 1 to 5 of 1000 patients: rash; pruritus; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision. Although relationship to drug usage is not clear, sleep disturbances have been reported. The oculomucocutaneous syndrome associated with practolol has not been reported with nadolol. The following adverse reactions may also occur: **Central Nervous System** — reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss; emotional lability with slightly clouded sensorium, decreased performance on neuropsychometrics. **Gastrointestinal** — mesenteric arterial thrombosis; ischemic colitis. **Hematologic** — agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura. **Allergic** — fever combined with aching and sore throat; laryngospasm; respiratory distress. **Miscellaneous** — reversible alopecia; Peyronie's disease; erythematous rash; arterial insufficiency.

Bendroflumethiazide — **Gastrointestinal System** — anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis. **Central Nervous System** — dizziness, vertigo, paresthesia, headache, xanthopsia. **Hematologic** — leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia. **Dermatologic-Hypersensitivity** — purpura, photosensitivity, rash, urticaria, necrotizing angiitis (vasculitis, cutaneous vasculitis). **Cardiovascular** — orthostatic hypotension may occur. **Other** — hyperglycemia, glycosuria, occasional metabolic acidosis in diabetics, hyperuricemia, allergic glomerulonephritis, muscle spasm, weakness, restlessness. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.

OVERDOSAGE: Nadolol may cause excessive bradycardia, cardiac failure, hypotension, or bronchospasm if overdosed. Overdosage of thiazides may cause lethargy, which may progress to coma within a few hours, with minimal depression of respiration and cardiovascular function and without evidence of serum electrolyte changes or dehydration. Gastrointestinal irritation and hypermotility may occur. Transitory increase in BUN and serum electrolyte changes may occur, especially in patients with renal impairment.

Treatment — Nadolol can be removed from the general circulation by hemodialysis. In determining duration of corrective therapy, take note of the long duration of the effect of nadolol. In addition to gastric lavage, employ the following measures, as appropriate. **Excessive Bradycardia** — Administer atropine (0.25 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously. **Cardiac Failure** — Administer a digitalis glycoside and diuretic. It has been reported that glucagon may also be useful in this situation. **Hypotension** — Administer vasopressors, e.g., epinephrine or levarterenol. (There is evidence that epinephrine may be the drug of choice.) **Bronchospasm** — Administer a $beta_2$-stimulating agent and/or a theophylline derivative. **Stupor or Coma** — Supportive therapy as warranted. **Gastrointestinal Effects** — Symptomatic treatment as needed. **BUN and/or Serum Electrolyte Abnormalities** — Institute supportive measures as required to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function.

DOSAGE AND ADMINISTRATION: DOSAGE MUST BE INDIVIDUALIZED. Patients with renal failure require adjustment in dosing interval; see package insert for dosage in these patients.

Consult package insert before prescribing CORZIDE (Nadolol-Bendroflumethiazide Tablets).

HOW SUPPLIED: Available as scored tablets containing 40 mg nadolol combined with 5 mg bendroflumethiazide and 80 mg nadolol combined with 5 mg bendroflumethiazide in bottles of 100.

SQUIBB

Innovators in cardiovascular medicine

© 1985 E. R. Squibb & Sons, Inc., Princeton, NJ 08540

505-511

Issued: December 1985

In California, Theo-Dur is the only oral theophylline that delivers an essentially equal dose every hour.

But only if you say so.

℞

Dispense as written

The only zero-order oral theophylline.

THEO-DUR®

(theophylline anhydrous) Sustained Action Tablets

Please see next page for brief summary of prescribing information.

The Endangered Species?

They look happy, healthy and vigorous. The all-American family. But are they as healthy as they look, or will they become the endangered species?

The solvents, thinners and chemicals at his job are far more harmful than he realizes. The herbicides and pesticides that contaminate their food are just as hazardous. The DDT and PCBs that have been found in the fresh fish she serves are a dangerous addition to their diet.

The environmental toxins they encounter every day of their lives makes them prime candidates for serious health problems—from infertility, to neurologic disorders, to cancer. Now you can discover whether your patients' vague, nonspecific symptoms such as fatigue, headache, loss of memory are the result of exposure to toxic substances. Male sterility, immune suppression, peripheral neuropathy, organic brain syndromes, hepatitis and other diseases have been linked to exposure to toxins.

Pacific Toxicology Laboratories is the first and only clinical diagnostic laboratory in the Western United States specializing in testing human samples—blood, urine, adipose tissue—for 33 different environmental toxins.

We provide you with screening tests for volatile solvents, PCBs, organochlorine pesticides such as DDT, and other hazardous substances. We deliver the results in 48 to 72 hours. Our staff of M.D. and Ph.D. toxicologists and clinical chemists give you a detailed analysis and interpretation of our findings.

Pacific Toxicology Laboratories supplies the glassware and instructions necessary for collecting and shipping samples. For information and materials call toll-free (800) 23-TOXIC in California, (800) 32-TOXIC outside California, or (213) 479-4911 in the Los Angeles area.

Yes, please send me more information about the "Endangered Species" screening tests.

PHYSICIANS NAME

ADDRESS

CITY STATE

TELEPHONE

PACIFIC TOXICOLOGY LABORATORIES

1545 PONTIUS AVENUE, LOS ANGELES, CA 90025, (213) 479-4911

A PRESCRIPTION FOR PHYSICIANS

Bothered by:

* Too much paperwork?
* The huge burden of office overhead?
* Malpractice insurance costs?
* Not enough time for the family?
* No time to keep current with technology and new methods?
* No time or money for professional development?

Join the Air Force Medical Team, we'll provide the following:

* Competent and dedicated professional staff.
* Time for patients and to keep professionally current.
* Financial security, a generous retirement for those who qualify.



* If qualified, unlimited professional development.
* Medical facilities all round the world.
* 30 days of vacation with pay each year.
* Complete medical and dental care.
* Low cost life insurance.

Want to find out more? Contact you nearest Air Force recruiter for information at no obligation.

DOCTORS IN EAST WASHINGTON-OREGON-NEVADA, MONTANA, IDAHO, UTAH, OR WEST WYOMING CALL

CAPTAIN STEVE BENTLEY (801) 524-4008 COLLECT

AIR FORCE

A great way of life.

In 7 of 10 anxious geriatrics...

Anxiety and depressive symptoms go hand in hand.



Xanax effectively relieves anxiety with associated depressive symptoms.



In a recent clinical study[1] of 83 geriatric patients with clinical anxiety, 73% were diagnosed as having symptoms of depressed mood.

XANAX is well suited for therapy because it demonstrates greater efficacy than does placebo in reducing the Hamilton Anxiety Rating Scale Total Score and individual items, including depressed mood (see Figure).

With clinical advantages for geriatric patients.

- Effectively relieves the symptoms of anxiety
- Also relieves anxiety with associated depressed mood
- Well tolerated—side effects, if they occur, are generally observed at the beginning of therapy and usually disappear with continued medication. Drowsiness and light-headedness were the most commonly reported adverse reactions
- Does not cause cardiovascular toxicity
- **Specific geriatric dosage**—0.25 mg, two or three times daily

1. Cohn JB: Double-blind safety and efficacy comparison of alprazolam and placebo in the treatment of anxiety in geriatric patients. *Curr Ther Res* 1984;35(1):100-112.

Xanax® 0.25 mg Tablets
alprazolam Ⓒ IV

Upjohn 100 A Century of Caring 1886·1986

© 1986 The Upjohn Company
Kalamazoo, Michigan 49001, USA

Please see adjacent page for brief summary of prescribing information.

Team support. Personalized, expert, responsive services, provided every day and when our members need it most.

THE DOCTORS' COMPANY

The Professionals in Professional Liability Insurance

401 WILSHIRE BOULEVARD, SANTA MONICA, CA 90401 (213)451-3011 • (800)352-7271

Before prescribing, see complete prescribing information in SK&F CO. literature or *PDR*. The following is a brief summary.

★ **WARNING**

This drug is not indicated for initial therapy of edema or hypertension. Edema or hypertension requires therapy titrated to the individual. If this combination represents the dosage so determined, its use may be more convenient in patient management. Treatment of hypertension and edema is not static, but must be reevaluated as conditions in each patient warrant.

Contraindications: Concomitant use with other potassium-sparing agents such as spironolactone or amiloride. Further use in anuria, progressive renal or hepatic dysfunction, hyperkalemia. Pre-existing elevated serum potassium. Hypersensitivity to either component or other sulfonamide-derived drugs.

Warnings: Do not use potassium supplements, dietary or otherwise, unless hypokalemia develops or dietary intake of potassium is markedly impaired. If supplementary potassium is needed, potassium tablets should not be used. Hyperkalemia can occur, and has been associated with cardiac irregularities. It is more likely in the severely ill, with urine volume less than one liter/day, the elderly and diabetics with suspected or confirmed renal insufficiency. Periodically, serum K^+ levels should be determined. If hyperkalemia develops, substitute a thiazide alone, restrict K^+ intake. **Associated widened QRS complex or arrhythmia requires prompt additional therapy.** Thiazides cross the placental barrier and appear in cord blood. Use in pregnancy requires weighing anticipated benefits against possible hazards, including fetal or neonatal jaundice, thrombocytopenia, other adverse reactions seen in adults. Thiazides appear and triamterene may appear in breast milk. If their use is essential, the patient should stop nursing. Adequate information on use in children is not available. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. Possible exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics.

Precautions: The bioavailability of the hydrochlorothiazide component of 'Dyazide' is about 50% of the bioavailability of the single entity. Theoretically, a patient transferred from the single entities of Dyrenium (triamterene, SK&F CO.) and hydrochlorothiazide may show an increase in blood pressure or fluid retention. Similarly, it is also possible that the lesser hydrochlorothiazide bioavailability could lead to increased serum potassium levels. However, extensive clinical experience with 'Dyazide' suggests that these conditions have not been commonly observed in clinical practice. Do periodic serum electrolyte determinations (particularly important in patients vomiting excessively or receiving parenteral fluids, and during concurrent use with amphotericin B or corticosteroids or corticotropin [ACTH]). Periodic BUN and serum creatinine determinations should be made, especially in the elderly, diabetics or those with suspected or confirmed renal insufficiency. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate coma in patients with severe liver disease. Observe regularly for possible blood dyscrasias, liver damage, other idiosyncratic reactions. Blood dyscrasias have been reported in patients receiving triamterene, and leukopenia, thrombocytopenia, agranulocytosis, and aplastic and hemolytic anemia have been reported with thiazides. Thiazides may cause manifestation of latent diabetes mellitus. The effects of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary. Clinically insignificant reductions in arterial responsiveness to norepinephrine have been reported. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine. Triamterene is a weak folic acid antagonist. Do periodic blood studies in cirrhotics with splenomegaly. Antihypertensive effects may be enhanced in post-sympathectomy patients. Use cautiously in surgical patients. Triamterene has been found in renal stones in association with the other usual calculus components. Therefore, 'Dyazide' should be used with caution in patients with histories of stone formation. A few occurrences of acute renal failure have been reported in patients on 'Dyazide' when treated with indomethacin. Therefore, caution is advised in administering nonsteroidal anti-inflammatory agents with 'Dyazide'. The following may occur: transient elevated BUN or creatinine or both, hyperglycemia and glycosuria (diabetic insulin requirements may be altered), hyperuricemia and gout, digitalis intoxication (in hypokalemia), decreasing alkali reserve with possible metabolic acidosis. 'Dyazide' interferes with fluorescent measurement of quinidine. Hypokalemia is uncommon with 'Dyazide', but should it develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods. Corrective measures should be instituted cautiously and serum potassium levels determined. Discontinue corrective measures and 'Dyazide' should laboratory values reveal elevated serum potassium. Chloride deficit may occur as well as dilutional hyponatremia. Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. Serum PBI levels may decrease without signs of thyroid disturbance. Calcium excretion is decreased by thiazides. 'Dyazide' should be withdrawn before conducting tests for parathyroid function.

Thiazides may add to or potentiate the action of other antihypertensive drugs.

Diuretics reduce renal clearance of lithium and increase the risk of lithium toxicity.

Adverse Reactions: Muscle cramps, weakness, dizziness, headache, dry mouth; anaphylaxis, rash, urticaria, photosensitivity, purpura, other dermatological conditions; nausea and vomiting, diarrhea, constipation, other gastrointestinal disturbances; postural hypotension (may be aggravated by alcohol, barbiturates, or narcotics). Necrotizing vasculitis, paresthesias, icterus, pancreatitis, xanthopsia and respiratory distress including pneumonitis and pulmonary edema, transient blurred vision, sialadenitis, and vertigo have occurred with thiazides alone. Triamterene has been found in renal stones in association with other usual calculus components. Rare incidents of acute interstitial nephritis have been reported. Impotence has been reported in a few patients on 'Dyazide', although a causal relationship has not been established.

Supplied: 'Dyazide' is supplied as a red and white capsule, in bottles of 1000 capsules; Single Unit Packages (unit-dose) of 100 (intended for institutional use only); in Patient-Pak™ unit-of-use bottles of 100.

BRS-DZ:L39

a product of

SK&F CO.

Carolina, P.R. 00630

© SK&F Co., 1985

The unique red and white Dyazide® capsule: Your assurance of SK&F quality.

The Benefits of Less

Low doses of hydrochlorothiazide can provide most of the antihypertensive effect of larger doses.[1]

Increasing dosage above 25 mg. daily or improving bioavailability will not lead to increased antihypertensive efficacy in the majority of patients, but can result in a higher incidence of hypokalemia, hyperuricemia and hyperglycemia.[2]

HYDROCHLOROTHIAZIDE: FLAT DOSE-RESPONSE CURVE[3]



For the benefits of low dose diuretic therapy* with the added benefit of potassium-sparing triamterene

PRESCRIBE

DYAZIDE®

25 mg Hydrochlorothiazide/**50 mg** Triamterene/SKF

*Not for initial therapy. See boxed warning.

1. Kaplan, N.: Systemic Hypertension: Therapy, in Braunwald, E. (ed.), Heart Disease. A Textbook of Cardiovascular Medicine, Philadelphia, W.B. Saunders Co., vol. 1, pp. 922-951.
2. Dialogues in Hypertension, Hypertension Update II: New Developments in Antihypertensive Therapy, Jan. 1985, Health Learning Systems Inc.
3. Adapted from Beerman, B., and Groschinsky-Grind, M.: Antihypertensive Effect of Various Dose of Hydrochlorothiazide and Its Relation to the Plasma Level of the Drug, Eur. J. Clin. Pharmacol. 13: 195-201, 1978.

SCPIE.
An enviable record of healthy growth and achievement.

In Perfect Health!

That's the professional opinion on SCPIE.

By every key test, SCPIE is strong...

Best's, the highly-respected, independent, national insurance rating bureau, has just given SCPIE its first rating, "A" (Excellent).

Assets: SCPIE has more assets than any other physician-owned company in California.

Reserves: SCPIE has reserves to pay all outstanding and anticipated claims.

Surplus: SCPIE maintains an adequate surplus as a cushion against unexpected losses.

Membership: SCPIE is strong and growing, with more members in Southern California than any other company.

Management: SCPIE's all-physician Board of Governors and professional insurance staff have proven that conservative management pays off.

Underwriting: Physician control helps keep losses down.

Why is SCPIE the leader?

SCPIE has the lowest overhead of any physician-owned company in Southern California.

For the sixth year, SCPIE is repaying the Capital Contributions which physicians put up to start the company.

Returns of Capital Contributions are approved by the State Department of Insurance—further confirmation of SCPIE's strength.

SCPIE returns premium and investment income not needed to pay claims and expenses. In 1985 SCPIE is returning $7 million as Experience Credits for policy years 1976-81. This makes significant reductions in net premiums.

SCPIE is here to stay.

SCPIE has become the seventh largest writer of medical liability coverage in the entire nation. An enviable record of healthy growth and achievement.



scpie

Southern California Physicians Insurance Exchange

2029 Century Park East
Suite 2300
Los Angeles, CA 90067
(213) 552-8900

Sponsored by SOCAP: The medical associations and societies of Kern County, Los Angeles County, Orange County, San Bernardino County, San Luis Obispo County, Santa Barbara County and Ventura County.

Consider the causative organisms...



Ceclor®
cefaclor

250-mg Pulvules® t.i.d.

offers effectiveness against the major causes of bacterial bronchitis

H. influenzae, H. influenzae, S. pneumoniae, S. pyogenes
(ampicillin-susceptible) (ampicillin-resistant)

Brief Summary. Consult the package literature for prescribing information.

Indications and Usage: Ceclor* (cefaclor, Lilly) is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:

Lower respiratory infections, including pneumonia caused by *Streptococcus pneumoniae (Diplococcus pneumoniae), Haemophilus influenzae,* and *S. pyogenes* (group A beta-hemolytic streptococci).

Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to Ceclor.

Contraindication: Ceclor is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Warnings: IN PENICILLIN-SENSITIVE PATIENTS, CEPHALOSPORIN ANTIBIOTICS SHOULD BE ADMINISTERED CAUTIOUSLY. THERE IS CLINICAL AND LABORATORY EVIDENCE OF PARTIAL CROSS-ALLERGENICITY OF THE PENICILLINS AND THE CEPHALOSPORINS, AND THERE ARE INSTANCES IN WHICH PATIENTS HAVE HAD REACTIONS, INCLUDING ANAPHYLAXIS, TO BOTH DRUG CLASSES.

Antibiotics, including Ceclor, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs.

Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics (including macrolides, semisynthetic penicillins, and cephalosporins); therefore, it is important to consider its diagnosis in patients who develop diarrhea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening.

Treatment with broad-spectrum antibiotics alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is one primary cause of antibiotic-associated colitis.

Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, management should include sigmoidoscopy, appropriate bacteriologic studies, and fluid, electrolyte, and protein supplementation. When the colitis does not improve after the drug has been discontinued, or when it is severe, oral vancomycin is the drug of choice for antibiotic-associated pseudomembranous colitis produced by *C. difficile*. Other causes of colitis should be ruled out.

Precautions: *General Precautions* — If an allergic reaction to Ceclor* (cefaclor, Lilly) occurs, the drug should be discontinued, and, if necessary, the patient should be treated with appropriate agents, e.g., pressor amines, antihistamines, or corticosteroids.

Prolonged use of Ceclor may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs' test may be due to the drug.

Ceclor should be administered with caution in the presence of markedly impaired renal function. Under such conditions, careful clinical observation and laboratory studies should be made because safe dosage may be lower than that usually recommended.

As a result of administration of Ceclor, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedict's and Fehling's solutions and also with Clinitest* tablets but not with Tes-Tape* (Glucose Enzymatic Test Strip, USP, Lilly).

Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Usage in Pregnancy — Pregnancy Category B — Reproduction studies have been performed in mice and rats at doses up to 12 times the human dose and in ferrets given three times the maximum human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Ceclor* (cefaclor, Lilly). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers — Small amounts of Ceclor have been detected in mother's milk following administration of single 500-mg doses. Average levels were 0.18, 0.20, 0.21, and 0.16 mcg/ml at two, three, four, and five hours respectively. Trace amounts were detected at one hour. The effect on nursing infants is not known. Caution should be exercised when Ceclor is administered to a nursing woman.

Usage in Children — Safety and effectiveness of this product for use in infants less than one month of age have not been established.

Adverse Reactions: Adverse effects considered related to therapy with Ceclor are uncommon and are listed below.

Gastrointestinal symptoms occur in about 2.5 percent of patients and include diarrhea (1 in 70).

Symptoms of pseudomembranous colitis may appear either during or after antibiotic treatment. Nausea and vomiting have been reported rarely.

Hypersensitivity reactions have been reported in about 1.5 percent of patients and include morbiliform eruptions (1 in 100). Pruritus, urticaria, and positive Coombs' tests each occur in less than 1 in 200 patients. Cases of serum-sickness-like reactions (erythema multiforme or the above skin manifestations accompanied by arthritis/arthralgia and, frequently, fever) have been reported. These reactions are apparently due to hypersensitivity and have usually occurred during or following a second course of therapy with Ceclor. Such reactions have been reported more frequently in children than in adults. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy. No serious sequelae have been reported. Antihistamines and corticosteroids appear to enhance resolution of the syndrome.

Cases of anaphylaxis have been reported, half of which have occurred in patients with a history of penicillin allergy.

Other effects considered related to therapy included eosinophilia (1 in 50 patients) and genital pruritus or vaginitis (less than 1 in 100 patients).

Causal Relationship Uncertain — Transitory abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.

Hepatic — Slight elevations in SGOT, SGPT, or alkaline phosphatase values (1 in 40).

Hematopoietic — Transient fluctuations in leukocyte count, predominantly lymphocytosis occurring in infants and young children (1 in 40).

Renal — Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200).

[061782R]

Note. Ceclor* (cefaclor, Lilly) is contraindicated in patients with known allergy to the cephalosporins and should be given cautiously to penicillin-allergic patients.

Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. See prescribing information.

© 1984, ELI LILLY AND COMPANY

Lilly

Additional information available to the profession on request from Eli Lilly and Company, Indianapolis, Indiana 46285

Eli Lilly Industries, Inc.
Carolina, Puerto Rico 00630

400441

American College of Physicians presents...



Gateway to a Golden Medical Opportunity

67th ANNUAL SESSION
APRIL 10-13, 1986
MOSCONE CENTER

Join us in San Francisco for Internal Medicine's Premier Meeting!

- Plan your own CME curriculum from over 300 scientific presentations . . . covering 14 major internal medicine subspecialties
- Discuss your problem cases with medicine's leading teachers and clinicians
- Find out how the new science of Medical Informatics can help you now and in the future
- Learn how discoveries in the "New Genetics" are affecting clinical medicine
- Choose from either of two pre-meeting courses on Critical Care or Management of Acute Myocardial Infarction
- Bring your spouse and family to enjoy a full schedule of special activities

Send for your 1986 Annual Session Scientific Program Guide

6W02

YES, please mail me the '86 Program Guide

NAME

ADDRESS

CITY STATE ZIP

Telephone toll free:
(800) 523-1546
(In Pennsylvania:
(215) 243-1200)

☐ ACP member ☐ non-member

American College of Physicians
4200 Pine Street, Philadelphia, PA 19104

Classified Advertisements

The rate for each insertion is **$5 per line** (average six words per line) **with five line ($25) minimum.** Box number charge: $5 each month.

Classified display rates $50 per inch.

Copy for classified advertisements should be received not later than **the first of the month preceding issue. All copy must be typed or printed.** • Classified advertisers using Box Numbers forbid the disclosure of their identity. Your inquiries in writing will be forwarded to Box Number advertisers. The right is reserved to reject or modify all classified advertising copy in conformity with the decisions of the Advertising Committee.

Please Type or Print Advertising Copy

Classified Advertisements Are Payable in Advance

THE WESTERN JOURNAL OF MEDICINE
P.O. BOX 7602, SAN FRANCISCO, CA 94120-7602

PHYSICIANS WANTED

THORACIC VASCULAR GENERAL SURGEON—To associate with senior Surgeon. Well established referral practice. Salary plus percentage. Central California. Send curriculum vitae to Box 7001, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

INTERNIST or internal medicine subspecialist to associate with recently established Internist/Rheumatologist in growing Northern California community of 150,000. Incentives offered. Reply with CV to Rex Adams, MD; PO Box 5375, Modesto, CA 95352-5375.

BEAUTIFUL CALIFORNIA CENTRAL COAST—Eight man, multispecialty medical group, seeking a BC/BE Family Practice physician, with broad based practice interests. An expanding population demands that we plan for internal growth. Be prepared to step into an active, ready made practice with group practice conveniences and rewards. Excellent salary/ fringe benefits package leading to partnership buy-in opportunities. Address CV and references to: Patrick M. Quigley, Sr., Administrator, Valley Medical Group, 136 North Third St., Lompoc, CA 93436; (805) 736-1253.

ARIZONA BASED PHYSICIAN RECRUITMENT firm has opportunities Coast to Coast. "Professionals working with Professionals." Over 13 years experience. Call (602) 795-7474; or send CV to: Mitchell & Associates, Inc., 2761 N. Country Club Rd., Ste. 202, Tucson, AZ 85716.

BOARD CERTIFIED/ELIGIBLE GENERAL INTERNIST to join established three-man partnership in San Jose, California. Send CV to Mr Dave Wright, 675 E. Santa Clara St., San Jose, CA 95112.

FAMILY PRACTITIONER—South central California, growing, semirural, mountain community. Excellent practice opportunity with supportive medical staff. Contact: Larry Clements, Administrator, Tehachapi Hospital, PO Box 648, Tehachapi, CA 93561; (805) 822-3241.

INTERNIST—Urgently needed in Ketchum/Sun Valley multispecialty clinic. Will assume large practice of retiring internist. Excellent climate, unlimited recreation facilities and very good schools. Income dependent on productivity. Dr. Bryan Stone, PO Box 2198, Ketchum, ID 83340; (208) 726-9361.

FAMILY PHYSICIAN—Board certified or eligible to join the Family Practice Department of a busy, primary care based multispecialty group. Excellent opportunity for growth. Contact Shane Spray, Administrator, Skagit Valley Medical Center, 1400 E. Kincaid, Mt. Vernon, WA 98273; (206) 428-2524.

PHYSICIANS WANTED

NORTHERN CALIFORNIA, EMERGENCY MEDICINE—Full-time positions available in the Emergency Room at The University of California Davis Medical Center. The University serves a large region of Northern California and is a major trauma center. Emergency physicians teach and supervise medical students and housestaff in addition to treating patients, primarily. Opportunities exist for involvement in other School of Medicine teaching activities. Applicants should send Curriculum Vitae to Robert W. Derlet, MD, University of California Davis Medical Center, 2315 Stockton Blvd., Department of Emergency Medicine, Trailer 1219, Sacramento, California 95817.

ENT position open with 35-member multispecialty group; BC/BE; immediate opening. Excellent practice opportunity; full range of benefits plus immediate Shareholder status; all practice costs paid. Central Coast of California. Submit CV to Colin J. Wells, MD, Recruitment Coordinator, 1235 Osos St., San Luis Obispo, CA 93401.

FAMILY PHYSICIAN—BC/BE, to join busy practice in family-oriented community on outskirts of metropolitan area. OB skills required. New office next to community hospital. Recruitment supported by medical staff/hospital. Unexcelled skiing and outdoor recreation twenty minutes away. Guaranteed first-year minimum. Send CV to Judith Kirstein, MD, Box 688, West Jordan, UT 84084.

OTOLARYNGOLOGIST position open with 33 member multispecialty group. Board certification or eligibility required. Excellent practice opportunity; full range of benefits, including immediate shareholder status, retirement program, all practice costs paid. For more information contact: Colin Wells, MD, Recruitment Coordinator or David Graham, Associate Administrator, San Luis Medical Clinic, Ltd., 1235 Osos St., San Luis Obispo, CA 93401.

FAMILY PRACTITIONER, position available with 35 member multispecialty group; BC/BE; immediate opening; full range of benefits plus immediate shareholder status; excellent opportunity; Central Coast of California. Submit CV to Colin J. Wells, MD, San Luis Medical Clinic, Ltd., 1235 Osos St., San Luis Obispo, CA 93401.

GENERAL SURGEON—Board certified Surgeon seeking qualified associate for well established practice in rural northern California community of Healdsburg located 65 miles north of San Francisco. Send CV to Healdsburg General Hospital, 1375 University St., Healdsburg, CA 95448, Attention, Duane Kenward, Executive Director.

PHYSICIANS WANTED

RURAL COLORADO: General Surgeon, BC/BE to join six physicians in growing multispecialty group. Salaried position with not-for-profit corporation. Excellent opportunity for person interested in rural living, mountain recreation, health care delivery for medically underserved populations. Send CV to Michael Bloom, 204 Carson Ave., Alamosa, CO 81101; (303) 589-5161. EOE.

SAN FRANCISCO BAY AREA: Our group has part-time and full-time opportunities available for physicians specializing in family practice, emergency medicine, or internal medicine. Opportunities available at two separate facilities, both located approximately one hour drive from San Francisco. The facilities include an Urgent Care Center offering 12-hour shifts on weekdays or weekends, and a separate contract facility performing employee physical exams weekdays only. Paid malpractice and competitive hourly compensation with small, high quality group. Send CV to the Chase Dennis Group, 873 Corcoran Ct., Benicia, CA 94510.

RURAL COLORADO: Family practice, BC/BE Family Practitioner to join four FPs in growing multispecialty group. Salaried position with not-for-profit corporation. Excellent opportunity for person interested in rural living, mountain recreation, health care delivery for medically underserved populations. Send CV to Michael Bloom, 204 Carson Ave., Alamosa, CO 81101; (303) 589-5161.

SOUTH CENTRAL WYOMING—Immediate practice opportunity for Board certified or Board eligible Orthopedic Surgeon and Urologist. Well equipped JCAH hospital. Progressive medical staff of 13 caring for a service area of approximately 20,000 population. No state or city income tax. Relocation incentives. Superior hunting, fishing, camping, snowmobiling. Three hours to Colorado ski area, five hours to Jackson Hole. One and one-half hours to the mountains. If interested, please send CV and references to: T. Goldfarb, MD, Chairman, Recruiting Committee or Richard Mills, Executive Director, Memorial Hospital of Carbon County, Rawlins, WY 82301; (307) 324-2221.

CALIFORNIA, SAN FRANCISCO BAY AREA: Full-time career Emergency Physician wanted for high volume Emergency Department/Paramedic Base Station. Emergency Medicine Board certified or Board-ready, mandatory to participate in a group of twenty full-time staff physicians seeing over 300 patients per day. Salaried position, excellent benefits include three weeks paid vacation; one week CME; paid malpractice, health and life insurance; corporate shareholdership in three years. Send CV or contact David Gallagher, MD, 27400 Hesperian Blvd., Hayward, CA 94545.

PATHOLOGIST—Assistant Director/Pathologist position open in fully-equipped modern 106 bed hospital. Income guarantee. Family-oriented community of Clovis, New Mexico. For additional information, submit CV to: Bill Norris, Southwest Community Health Services, PO Box 26666, Albuquerque, NM 87125-6666.

INTERNAL MEDICINE—Join an established, lucrative practice located in the prime resort community of Ruidoso, New Mexico. Financial assistance available. Private practice/sharing expenses or possible association. Prefer background in GI. Submit CV to: Bill Norris, Southwest Community Health Services, PO Box 26666, Albuquerque, NM 87125-6666.

BEAUTIFUL CALIFORNIA CENTRAL COAST—Eight man, multispecialty medical group, seeking a Physician BC/BE in Internal Medicine, with broad based practice interests. An expanding population demands that we plan for internal growth. Be prepared to step into an active, ready made practice with group practice conveniences and rewards. Excellent salary/fringe benefits package leading to partnership buy-in opportunities. Address CV and references to: Patrick M. Quigley, Sr., Administrator, Valley Medical Group, 136 North Third St., Lompoc, CA 93436; (805) 736-1253.

(Continued on Page 263)

(Continued from Page 261)

PHYSICIANS WANTED

ANESTHESIOLOGIST NEEDED for Central Washington community of 12,000 located on Moses Lake. Fifty bed progressive hospital with active medical staff of 25 does 150 surgical cases per month. Dry climate, water sports, excellent fishing and hunting. For further information contact The Friedrich Group, Inc., 9284 Ferncliff Northeast, Bainbridge Island, WA 98110; or call (206) 842-5248.

GENERAL INTERNIST (BC/BE). United States trained to associate with four young generalists in rapid growth area of central California. Area remains open for establishing a new practice. Near Yosemite and other year-round recreation. Send CV to Dr Cecil Bullard, 5339 N. Fresno St., #107D, Fresno, CA 93710.

FACULTY POSITION AVAILABLE: Eighteen-resident fully accredited program affiliated with University of Washington. City of 105,000 with multiple cultural and recreational opportunities. Excellent salary and benefits. Board certified in family practice required. Send CV to John J. Mohr, MD, Director, 777 N. Raymond St., Boise, ID 83704.

OB/GYN: Multispecialty group in Northwest Washington desires second Obstetrician. Excellent practice opportunity, full range of benefits, early partnership status, all practice costs paid. For more information contact Shane Spray, Administration, 1400 E. Kincaid, Mount Vernon, WA 98273; (206) 428-2524.

RESEARCH ASSISTANT: Will develop methods for the preparation of new drugs for the treatments of cancer and heart diseases. Requires BS in biological science, and two years of experience. Job site/interviews San Diego, California. Salary $1,851 per month. Send this ad and your résumé to NOF job #5394, PO Box 9560, Sacramento, CA 95823-0560 not later than February 28, 1986.

HEALTH OFFICER for public health district composed of all cities and unincorporated area in Snohomish County, Washington; total population 373,000. MD with MPH required. Competitive compensation plus attractive benefits. Send curriculum vitae to Claris Hyatt, MD, Health Officer, Snohomish Health District, Everett, WA 98201; (206) 259-9383.

OB/GYN—Southern California solo practitioner seeking male/female BE/BC physician to join fast growing practice. Must be dedicated to private care. Fully equipped office. Send CV to Ziyad A. Ghabra, MD, 907 W. Lancaster Blvd., Lancaster, CA 93534.

CALIFORNIA. Rapidly growing rural mountain area. Family Practice, OB/GYN, Pediatrician needed to complement current medical staff. Solo or partnership practice available. Joint venture possibilities with hospital. Contact or send CV to Mr Richard Wing, Administrator, Mark Twain Hospital, 768 Mountain Ranch Rd., San Andreas, CA 95249; (209) 754-3521.

GERIATRICIAN/INTERNIST to contract 16 hours per month as consultant to multidisciplinary geriatric assessment team in San Francisco Bay area. No direct patient responsibility. Occasional teaching responsibilities. BC/BE. California license required. CV to Ralph Bien, MD, Marin County Community Mental Health, 1030 Sir Francis Drake Blvd., Kentfield, CA 94904.

BAY AREA, multispecialty medical group, looking for Board certified/eligible medical Internist. Interested physicians should contact Donald Lass, Administrator at (415) 785-5000 or mail your curriculum vitae to 27212 Calaroga Ave., Hayward, CA 94545.

CALIFORNIA AND WESTERN UNITED STATES—FP, GP, Industrial, Ortho, OB/GYN and other specialties. If you are considering the West Coast—let's talk. Our staff is comprised of ex-administrators and current MDs. Call the professionals at: Physicians Search Associates Agency, Inc., 1835 Orangewood Ave., Ste. 323, Orange, CA 92668; (714) 978-6899.

PHYSICIANS WANTED

OPHTHALMOLOGIST. Responsible for providing all phases of medical and surgical eye care for private medical group including examination of patients, diagnosis of illness, selection and interpretation of lab tests, prescription of therapy, and all surgical procedures including phaco emulsification and yag laser surgery. Minimum job requirements include MD degree, one year internship, three years ophthalmology residency, one year fellowship training performing phaco emulsification and yag laser surgery under direction of anterior segment surgeon, current California physician and surgeon license and current Controlled Substances Registration Certificate. Job is full-time and permanent at $60,000/year. Job site is Alhambra, California. Send this ad and your résumé to Job #3953, PO Box 9560, Sacramento, CA 95823-0560 no later than March 1, 1986.

THE UNIVERSITY OF UTAH, Department of Internal Medicine, is seeking two critical care subspecialists for full-time tenure track faculty positions at the instructor or assistant professor level as co-directors of the Medical Intensive Care Unit. Should be Board certified or eligible by the American Board of Internal Medicine in both Internal Medicine and the subspecialty of Pulmonary Diseases. Applications will be accepted until April 1, 1986. Applications submitted after deadline will be accepted if position not filled. Send CV to A. D. Renzetti, Jr., MD, Department of Medicine, University of Utah Health Sciences Center, Salt Lake City, UT 84132.

CALIFORNIA, NORTHERN. Board certified or eligible Ophthalmologist to join long established solo practice with transfer of administrative responsibility and surgery when able to assume same. Ophthalmologist owning practice desires to remain part-time for several years. Send résumé to Box 106, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

PHYSICIAN SHORTAGE—Family Medicine Physicians needed in Seattle suburban community now. In response to community need, a major full-service hospital is encouraging the development of Family Medicine Practices. Commercial financing contacts are being arranged by the hospital. This high-growth, high-employment community has some existing practices available. For more information, please call or write The Friedrich Group, Inc., 9284 Ferncliff N.E., Bainbridge Island, WA 98110; (206) 842-5248.

ASSOCIATE IN PEDIATRICS: Kern Medical Center, Bakersfield, California, a Southern California teaching hospital affiliated with UCLA School of Medicine, seeks an Associate in its Department of Pediatrics. Prerequisites include eligibility or certification by the American Board of Pediatrics, strong interest in child/sexual abuse, teaching and qualifications for faculty appointment in the UCLA Department of Pediatrics. Compensation and benefits are competitive. Please reply with curriculum vitae to Jess Diamond, MD, Chairman, Kern Medical Center Department of Pediatrics, 1830 Flower St., Bakersfield, CA 93305; or telephone (collect) (805) 326-2263.

CARDIOLOGIST, INVASIVE—110-physician, multispecialty, prepaid group located in the San Francisco Bay area wishes to add another Cardiologist/Internist. Practice includes large volume of referrals for invasive procedures. Dopler-echo skills required. University affiliation available. Please contact: E. Andrews Neal, MD, The Permanente Medical Group, Inc., 260 International Circle, San Jose, CA 95119; telephone (collect) (408) 972-3000.

FAMILY PRACTICE-PEDIATRICIAN. Excellent professional opportunity in beautiful north Idaho. For information (208) 784-1221, ext. 304. Shoshone Medical Center, Jacobs Gulch, Kellogg, ID 83837.

OB/GYN AND FP PHYSICIAN WITH OB SKILLS to join female practitioner in the north coast historical town of Mendocino, California. Possibility for partnership in relaxed, friendly community. PO Box 819, Mendocino, CA 95460; (707) 937-4272.

PHYSICIANS WANTED

INTAKE PHYSICIAN—For Neurology practice. Conduct intake exams; administer diagnostic tests; prepare diagnoses; counsel patients. Requires MD plus completed one year internship in general medicine. Also at least two years experience in medical practice in internal medicine, gastroenterology, or neurology. Must have experience in internal medicine, basic gastroenterology, and basic neurology. Also experience in patient histories, physicals, lab test orders and interpretations, nasogastric tube placement, endoscopy, rectosigmoidoscopy, rectal exams, abdominal, pleural, and lumbar taps, spinal fluid analysis, electroencephalograph testing, CT scan interpretations. Must have experience in patient counseling; fluent in English and Spanish. Salary: $45,255 per year. Qualified applicants send résumé or application letter to: AZ DES Job Service, Attn. 732-A Re: 0801871, PO Box 6123, Phoenix, AZ 85005. (Job Location: Tucson. Employer paid ad. Proof of authorization to work in United States required, list in résumé or application letter.)

CHEMISTRY TECHNOLOGIST—Measures radioactive isotopes in therapeutic, diagnostic and tracer studies. Performs qualitative and quantitative chemical analyses of body fluids and exudates. Tests body specimens for presence of metabolic substances, chemicals, drugs and poisons. Prepares solutions for chemical analyses. Calibrates and maintains equipment used in quantitative/qualitative analyses by using atomic absorption spectrophotometer and gas chromatographe. Job site: Santa Ana. 40 hour/week. $1,908/month. BA (Chemistry), 2 years experience. Send ad and résumé to Job #NOF 5409, PO Box 9560, Sacramento, CA 95823-0560 not later than March 3, 1986.

WANTED: Board certified General Internist to join three others in a busy, progressive practice in the Sierra foothills. Beautiful surroundings, but close to urban centers. New facility. Contact Dennis A. Nousaine, MD, FACP, 815 Court St., Ste. 7, Jackson, CA 95642.

INTERNIST, GP OR REHAB MD needed for busy clinic in San Jose, California, in the heart of Silicon Valley. 55 miles from San Francisco. Practice mainly musculoskeletal with concomitant organic related problems. Full- or part-time. Contact Dr Brody, South Bay Health and Fitness Clinic, (408) 947-8088.

CAREER OPPORTUNITY FOR FAMILY PHYSICIAN with well established group in Southern California. Full partnership available after trial period. Beautiful family type community in San Diego County. Résumé to: Peggy Smith, Penn Elm Medical Group, 815 East Pennsylvania Avenue, Escondido, CA 92025.

CLINICAL DIRECTOR AND PROFESSOR: San Francisco campus of Oriental medicine college; teach courses in acupuncture and traditional Oriental medicine in English, prepare coursework which integrates traditional concepts and theories of Oriental medicine with modern Western medical sciences. Supervise advanced students in school clinic in acupuncture and practice of Oriental medicine. Minimum requirement MSc in Anatomy or Physiology or Western medical sciences and 5 years experience in practice of acupuncture and Oriental medicine. 40 hour/week and $35,000/year. Send résumé to Job No. MV6524, PO Box 9570, Sacramento, CA 95823-0570 with this ad, not later than March 10, 1986.

SAN FRANCISCO—One year fellowship in Psychosomatic Medicine and Consultation Liaison Psychiatry offered by St. Mary's Medical Center, a 550 bed private teaching hospital. Supervised clinical, teaching, and administrative experience in unique Med-Psych inpatient unit, Med-Surg wards, Psychiatry and Medicine Clinics, and Sleep Disorders Center. Board eligibility in Psychiatry, Neurology or Medicine required. Contact: D. Nevins, MD, St. Mary's Medical Center, 450 Stanyan St., San Francisco, CA 94117.

(Continued on Page 266)

Essential reading for every physician



The July issue of the **New York State Journal of Medicine** is the most comprehensive and disturbing ever published by a medical journal on the subject of smoking.

SEND A COPY TO COLLEAGUES AND MEDICAL STUDENTS in the US and abroad who might not normally receive the Journal. Or order an extra copy for your patients or yourself.

NOTE: the extra press run of The World Cigarette Pandemic Part 1 (December 1983 issue) sold out quickly. The issue has been updated and republished as *The Cigarette Underworld* ($9.95 plus $1.50 postage). Copies may be ordered from Lyle Stuart, Inc., 120 Enterprise Avenue, Secaucus, NJ 07094.

An extra press run has enabled the NEW YORK STATE JOURNAL OF MEDICINE to offer single or bulk copies of its recent issue on the world cigarette pandemic. As the official publication of the Medical Society of the State of New York since 1900, the *Journal* is one of the foremost independent peer-reviewed general medical journals in the country. Providing timely and stimulating commentary, challenging research papers, analysis of clinical trends, debate on topical issues, and in-depth coverage of medical news, the *Journal* makes important reading—and a welcome gift—to physicians and students in the United States or abroad. A free copy of the July issue will be included with each subscription.

WJ2/86

ORDER FORM

Quantity	Per Copy*
1	$7.50
2-9	$7.00
10-24	$6.50
25-49	$6.00
50-99	$5.50
100-149	$5.00
150-500	$4.00

Name_____

Address_____

City/State/Zip_____

Please send_____copies of July 1985 issue of the Journal.

Enter my subscription to the Journal. ☐ $25.00 U.S. & Canada; ☐ $30.00 Foreign

Total amount enclosed $_____ ***Note:** Domestic postage included. Please add New York state & local sales tax where applicable, or sales tax exemption certificate. Foreign postage additional.

Mail to: Circulation Department, **New York State Journal of Medicine**
420 Lakeville Rd., P.O. Box 5404, Lake Success, N.Y. 11042.

(Continued from Page 263)

PHYSICIANS WANTED

OB/GYN, FAMILY PRACTICE, ORTHOPEDIC SURGEON—SEATTLE. OB/GYN opening with medical group. Position also available in Seattle suburb with private practitioner. FP and ORS are hospital sponsored. For details, call Eloise Gusman, 1 (800) 535-7698 or (504) 893-4879. PO Box 1685, Covington, LA 70434-1685.

WESTERN U.S. OPENINGS

Several multi-specialty groups and clinics have asked us to recruit for over 100 positions of various specialties.

Western States Physician Search
240 West Shaw, Suite C
Clovis, CA 93612
(209) 297-7748

PRACTICES AVAILABLE

GREAT LAS VEGAS general practice for sale. $200,000 plus on a four-day work week. Terms. Please reply Box 42100, Las Vegas, NV 89116.

PEDIATRIC PRACTICE—SEATTLE. Own your own practice in premier group. Excellent income. Available late 1986. Confidence assured. Send CV to Box 7011, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

FOR SALE: Pediatric Practice, suburban San Francisco area, busy two doctor office; established over 35 years. Both partners retiring. Will introduce. TERMS. Contact Jack W. Singleton, MD, 20094 Mission Blvd., Hayward, CA 94541; (415) 276-2244.

SAN FRANCISCO INTERNAL MEDICINE PRACTICE FOR SALE—Prestigious, established. Fifteen years. In excellent medical building. Very desirable and pleasant practice. Great opportunity. Write to Box 102, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

WELL ESTABLISHED General-Family solo practice for sale immediately. Central California. $250,000/year gross. Can be easily expanded. Physician leaving area; entering specialty field. Reply Box 104, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

FAMILY PRACTICE FOR SALE: Retiring, gross over $225,000. Take over lease. Buy equipment. Ideal location. Next to busy hospital. No OB. Terms. Contact Leonard R. Akland, MD, 227 W. Janss Rd., Ste. 320, Thousand Oaks, CA 91360; (805) 495-0411.

INTERNAL MEDICINE PRACTICE for sale. Available summer or fall 1986. Well established. North area Sacramento. Reply Box 105, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

CLOSE TO RETIREMENT. Active general medical practice with own building for sale in beautiful Ruidoso, New Mexico. Horse racing, skiing. Please call (505) 257-4907; evenings (505) 257-4868.

CALIFORNIA: Orthopedics, Urology, Pulmonary, Otolaryngology, Surgery, Cardiology, Family, Internal, Pediatric, OB/GYN, Psychiatric, others. Contact Mary Bradshaw, Practice Broker/Recruiter, 21 Altamount Dr., Orinda, CA 94563; (415) 376-0762.

OFFICE TO SHARE

ELEGANT PLASTIC SURGERY SUITE to share 3,600 square feet, two fully equipped operating rooms, recovery and consultation rooms. Suitable for Plastic Surgeon or any surgical specialty. Contact: Raj Kanodia, MD, 1 (213) 276-3106; 9201 Sunset Blvd., Ste. 405, Los Angeles, CA 90069. Available February 1986.

SITUATIONS WANTED

UROLOGIST. Seventeen years solo practice in same location. Boards and FACS. Wishes relocation to SW, W, NW. All practice arrangements considered. CV on request. Box 7009, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

MEDICAL PRACTICES – BUYING OR SELLING

SELECTED MEDICAL PRACTICES FOR SALE

M-986 - LOS ANGELES - General Surgery/General Practice. Dr. retiring. Collecting $300,000+. Flexible terms.
M-944 - LONG BEACH - ORTHOPEDIC SURGERY - Gross $250,000. Retirement. Flexible transition and terms.
M-959 - SOUTH BAY - G.P. with Real Estate. Retirement.
M-974 - ORANGE COUNTY - G.P. Net $220,000. Free standing building location. Computerized lab.
M-983 - IRVINE - G.P. General Surgeon. Grossing $220,000. Relaxed schedule. Super opportunity.
M-958 - SAN GABRIEL VALLEY - GYN - Long established practice grossing $150,000. Refers all surgery & OB. Buyer performing GYN surgery. Would at least double practice volume.
M-995 - COMING UP - San Joaquin Valley - G.P. collects $250,000.

Professional Practice Sales
Serving the professions since 1966
Nationwide services

SO. CALIFORNIA 364 E. First St., Tustin, CA 92680 (714) 832-0230 (213) 938-9991
NO. CALIFORNIA 1428 Irving St., San Francisco, CA 94122 (415) 661-0700

SERVICES

PHYSICIAN ASSISTANTS—The California Academy of Physician Assistants maintains a free job listing for its members and prospective employers. For further information, call (213) 402-0441 or write the California Academy of Physician Assistants, PO Box 403, Norwalk, CA 90651-0403.

IF YOU ARE setting up a new medical practice or need help with your existing practice, please call Kate North/Medical Office Consultant, (206) 823-5639.

PROFESSIONAL RÉSUMÉ SERVICES. Curriculum vitae preparation for physicians. All fields. Mailing Services available. Prompt and confidential. Call toll free anytime. 1 (800) 6-CAREER. In PA, (215) 433-4112.

WAR: HMO/PPO, etc. are out to garner your patients. You can beat them, primary F/P; let me show you how to. Patient/Finders, 1848 Port Taggart, Newport Beach, CA 92660.

MISCELLANEOUS

TALK TO PATIENTS IN EVERYDAY SPANISH!

- "Mexican Spanish Pronunciation/Make Friends" cassette & manual: $13.95 **(SATISFACTION GUARANTEED)**
- Other cassettes, full tape courses, including course in **MEDICAL SPANISH**
- INTENSIVE COURSES IN SUNNY BAJA CALIFORNIA-Weekday, weekend & evening classes—minutes from San Diego
- **CEU's: Calif. BRN #06235**

Call or write for **FREE BROCHURES** today:

CALIFORNIA SPANISH LANGUAGE ASSOCIATION
189-J Correo Fronterizo, San Ysidro, CA 92073
(619) 544-0548

SEMINARS

HAWAII

Waikiki and/or Maui, Kauai, Big Island
CME Category I, ACEP and Nursing
Daily & weekly all year
For information and catalog call:
800 367-8047, Ext. 110

AMERICAN SEMINAR INSTITUTE
808 924-4000
307 Lewers St., PH
Honolulu, HI 96815

LOCUM TENENS

LOCUM TENENS SERVICE
WESTERN PHYSICIANS REGISTRY

. . . offers coverage for vacation or continuing education. To arrange coverage for your practice or to participate as temporary physician, contact: **Carol Sweig, Director, 1315 Evans Avenue, San Francisco, CA 94124; (415) 826-7676.**

CONFERENCES

THE WESTERN CONFERENCE ON ALCOHOL AND DRUG ABUSE will be held March 19-23, 1986, at the Hyatt Regency Hotel, Vancouver, British Columbia. It is sponsored by WESCAD Management Inc., and co-sponsored by the American Medical Society on Alcoholism and Other Drug Dependencies Inc. The CFPC, AAFP and AMSAODD have each approved CME study credit hours totaling 17, plus 2 for each Workshop attended. Write or call for Conference brochure: WESCAD Management Inc., 3075 Point Grey Rd., Vancouver, B.C., Canada V6K 1A7; (604) 734-7812.

CLASSIFIED INFORMATION
(415) 863-5522 EXTENSION 244

In moderate depression and anxiety

FEELING BETTER FASTER...

OVERNIGHT—SLEEP IMPROVED[1]

Sleep improved in 74% after only one *h.s.* dose in selected patients

FIRST WEEK—OTHER SOMATIC SYMPTOMS MARKEDLY REDUCED[1]



FOURTH WEEK—PATIENT COMPLIANCE WAS BETTER[2]

More than three times as many amitriptyline patients as Limbitrol patients dropped out of therapy because of side effects, although the incidence of side effects was similar. Caution patients against the combined effects of Limbitrol with alcohol or other CNS depressants and about activities requiring complete mental alertness, such as operating machinery or driving a car. In general, limit dosage to lowest effective amount in elderly patients.

References: 1. Data on file, Hoffmann-La Roche Inc., Nutley, NJ. **2.** Feighner JP, *et al: Psychopharmacology 61:*217-225, Mar 22, 1979.

Limbitrol®

Each tablet contains 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt) Ⓥ

Limbitrol® DS

Each tablet contains 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt) Ⓥ

A brighter perspective...sooner

Limbitrol® Ⓥ Tranquilizer–Antidepressant

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of moderate to severe depression associated with moderate to severe anxiety.

Contraindications: Known hypersensitivity to benzodiazepines or tricyclic antidepressants. Do not use with monoamine oxidase (MAO) inhibitors or within 14 days following discontinuation of MAO inhibitors since hyperpyretic crises, severe convulsions and deaths have occurred with concomitant use; then initiate cautiously, gradually increasing dosage until optimal response is achieved. Contraindicated during acute recovery phase following myocardial infarction.

Warnings: Use with great care in patients with history of urinary retention or angle-closure glaucoma. Severe constipation may occur in patients taking tricyclic antidepressants and anticholinergic-type drugs. Closely supervise cardiovascular patients. (Arrhythmias, sinus tachycardia and prolongation of conduction time reported with use of tricyclic antidepressants, especially high doses. Myocardial infarction and stroke reported with use of this class of drugs.) Caution patients about possible combined effects with alcohol and other CNS depressants and against hazardous occupations requiring complete mental alertness (*e.g.*, operating machinery, driving).

***Usage in Pregnancy:* Use of minor tranquilizers during the first trimester should almost always be avoided because of increased risk of congenital malformations as suggested in several studies. Consider possibility of pregnancy when instituting therapy; advise patients to discuss therapy if they intend to or do become pregnant.**

Since physical and psychological dependence to chlordiazepoxide have been reported rarely, use caution in administering Limbitrol to addiction-prone individuals or those who might increase dosage; withdrawal symptoms following discontinuation of either component alone have been reported (nausea, headache and malaise for amitriptyline; symptoms [including convulsions] similar to those of barbiturate withdrawal for chlordiazepoxide).

Precautions: Use with caution in patients with a history of seizures, in hyperthyroid patients or those on thyroid medication, and in patients with impaired renal or hepatic function. Because of the possibility of suicide in depressed patients, do not permit easy access to large quantities in these patients. Periodic liver function tests and blood counts are recommended during prolonged treatment. Amitriptyline component may block action of guanethidine or similar antihypertensives. When tricyclic antidepressants are used concomitantly with cimetidine (Tagamet), clinically significant effects have been reported involving delayed elimination and increasing steady state concentrations of the tricyclic drugs. Concomitant use of Limbitrol with other psychotropic drugs has not been evaluated; sedative effects may be additive. Discontinue several days before surgery. Limit concomitant administration of ECT to essential treatment. See Warnings for precautions about pregnancy. Limbitrol should not be taken during the nursing period. Not recommended in children under 12. In the elderly and debilitated, limit to smallest effective dosage to preclude ataxia, oversedation, confusion or anticholinergic effects.

Adverse Reactions: Most frequently reported are those associated with either component alone: drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating. Less frequently occurring reactions include vivid dreams, impotence, tremor, confusion and nasal congestion. Many depressive symptoms including anorexia, fatigue, weakness, restlessness and lethargy have been reported as side effects of both Limbitrol and amitriptyline. Granulocytopenia, jaundice and hepatic dysfunction have been observed rarely.

The following list includes adverse reactions not reported with Limbitrol but requiring consideration because they have been reported with one or both components or closely related drugs:

Cardiovascular: Hypotension, hypertension, tachycardia, palpitations, myocardial infarction, arrhythmias, heart block, stroke.

Psychiatric: Euphoria, apprehension, poor concentration, delusions, hallucinations, hypomania and increased or decreased libido.

Neurologic: Incoordination, ataxia, numbness, tingling and paresthesias of the extremities, extrapyramidal symptoms, syncope, changes in EEG patterns.

Anticholinergic: Disturbance of accommodation, paralytic ileus, urinary retention, dilatation of urinary tract.

Allergic: Skin rash, urticaria, photosensitization, edema of face and tongue, pruritus.

Hematologic: Bone marrow depression including agranulocytosis, eosinophilia, purpura, thrombocytopenia.

Gastrointestinal: Nausea, epigastric distress, vomiting, anorexia, stomatitis, peculiar taste, diarrhea, black tongue.

Endocrine: Testicular swelling and gynecomastia in the male, breast enlargement, galactorrhea and minor menstrual irregularities in the female, elevation and lowering of blood sugar levels, and syndrome of inappropriate ADH (antidiuretic hormone) secretion.

Other: Headache, weight gain or loss, increased perspiration, urinary frequency, mydriasis, jaundice, alopecia, parotid swelling.

Overdosage: Immediately hospitalize patient suspected of having taken an overdose. Treatment is symptomatic and supportive. I.V. administration of 1 to 3 mg physostigmine salicylate has been reported to reverse the symptoms of amitriptyline poisoning. See complete product information for manifestation and treatment.

Dosage: Individualize according to symptom severity and patient response. Reduce to smallest effective dosage when satisfactory response is obtained. Larger portion of daily dose may be taken at bedtime. Single *h.s.* dose may suffice for some patients. Lower dosages are recommended for the elderly.

Limbitrol DS (double strength) Tablets, initial dosage of three or four tablets daily in divided doses, increased up to six tablets or decreased to two tablets daily as required. Limbitrol Tablets, initial dosage of three or four tablets daily in divided doses, for patients who do not tolerate higher doses.

How Supplied: *Double strength (DS) Tablets,* white, film-coated, each containing 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt), and *Tablets,* blue, film-coated, each containing 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt). Available in bottles of 100 and 500; Tel-E-Dose® packages of 100; Prescription Paks of 50.

ROCHE

ROCHE PRODUCTS INC.
Manati, Puerto Rico 00701

In depression and anxiety

CLEARING SYMPTOMS FASTER...

NIH LIBRARY
3 1496 00284 9969

Tab - 301
Batch - 540
Lot - 1
WPNo - 0014

Limbitrol®

Each tablet contains 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt) (IV)

Limbitrol® DS

Each tablet contains 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt) (IV)

Once daily *h.s.* for improved compliance

ROCHE®

Copyright © 1985 by Roche Products Inc. All rights reserved.

Please see reverse side for references and summary of product information.